

Curriculum Vitae

Dr. Michael Lindsay Grayson*Private Address:*

██████████
 ████████████████████
 ██████████

Business Address:

Professor/Director,
 Infectious Disease Department
 Austin Hospital, Austin Health
 Studley Rd., Heidelberg
 Victoria, Australia 3084
 Tel: 61-3-9496-6676; FAX: 61-3-9496 6677; Mob: 0419-565-971
 Email: Lindsay.Grayson@austin.org.au

Date of Birth:

██████████

Place of Birth:

Bunbury, Western Australia

Citizenship:

Australian

Social status:

Married: Prof. Julie Bines, MB BS, MD, FRACP
 Two children: Kristian Jack, 29 ys; Tara Kate, 25 ys.

Education:

1968-1973

Caulfield Grammar School, Melbourne, Australia

1974-1979

Faculty of Medicine
 Monash University, Melbourne, Australia
 Final year ranking: top 10 students for 1979

Qualifications:

1979

Bachelor of Medicine, Bachelor of Surgery (Honours)
 Monash University, Australia

1988

Fellowship of the Royal Australasian College of Physicians

1990

Fellowship of the Australian Faculty of Public Health Medicine

1994

Doctor of Medicine Degree (M.D.), Monash University
 Thesis: *Antibiotic resistance in enterococci:
 Trends, Mechanisms and Treatment Alternatives*

1997

Master of Science (MSc) in Clinical Epidemiology & Clinical Effectiveness
 Harvard School of Public Health, Harvard Medical School, Boston, USA

2008

Fellowship of the Royal College of Physicians of Edinburgh

2009

Fellowship of the Royal College of Physicians, UK

2012

Fellow – Infectious Diseases Society of America (FIDSA)

Scholarships and Awards

- 1990 National Foundation for Infectious Diseases Travel Grant, USA
- 1990 Edward H. Kass Award for Clinical Excellence - Harvard Medical School
Massachusetts Society of Infectious Diseases
- 1994 Glaxo Award for Advanced Research in Infectious Diseases
Australasian Society for Infectious Diseases
- 1995 Rowden White Travelling Fellowship
Royal Australasian College of Physicians
- 2000 Inaugural Visiting Fellow
Malaysian Infectious Diseases Society, Kuala Lumpur and Sabah, Malaysia
- 2006 Wyeth Award, Best Original Research article in Medical Journal of Australia for
2005, Australian Medical Association
- 2008 *Clinical Infectious Diseases* Award for Outstanding Review.
Journal: *Clinical Infectious Diseases*, 2008
- 2009 Wyeth Award, Best Original Research article in Medical Journal of Australia for
2008, Australian Medical Association
- 2009 Sir Richard Stawell Memorial Prize, Best Original Research article “on a medical
subject of clinical significance” in Medical Journal of Australia in 2008, Australian
Medical Association (Victoria)
- 2011 World Health Organization “Centre of Excellence” Award for the National Hand
Hygiene Initiative by Hand Hygiene Australia and Austin Health
- 2014 Inaugural Robert C. Moellering Visiting Professor
Infectious Diseases Division, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, USA. 23rd Oct. 2014
- 2015 Second prize. Fine sheep wool competition – medium class. Apollo Bay & Otways
Agricultural Show. March 2015. Apollo Bay, Victoria.
- 2015 Harold C. Neu Visiting Professor
Infectious Diseases Division, Department of Medicine, Columbia-Presbyterian
Medical Center, Columbia University, New York, USA. 18-20th May, 2015
- 2015 Fellowship, Melbourne Medical School Academy of Clinical Teachers,
University of Melbourne
- 2016 First prize. Fine sheep wool competition – medium class. Apollo Bay & Otways
Agricultural Show. March 2016. Apollo Bay, Victoria.
- 2016 Life Member. Australasian Society for Infectious Diseases (ASID)
- 2019 Order of Australia Award. AM – Member of the Order of Australia.

For services to medicine, especially in the field of Infectious Diseases

2020 Howard Florary Oration. Australian Society for Antimicrobials (ASA)

Government Awards

2002 Worksafe Victoria Award for Excellence and Innovation in Workplace Health and Safety. Category: Best Risk Solution – Introduction of safety cannulae and needleless systems in healthcare. Worksafe Victoria

2005 Minister's Award for Outstanding Team Achievement: *DeBug* Infection Prevention Program. Victorian Public Healthcare Awards.

2014 Health Innovation Award – Highly Commended. *Peripheral intravenous line safety initiative*. Victorian Public Healthcare Awards. Department of Health, Victoria.

Appointments

Current Appointments:

2000 - *current* Professor/Director
Infectious Disease & Microbiology Departments
Austin Hospital, Austin Health

2000 - *current* Professor of Medicine
University of Melbourne
Melbourne, Australia

1999- *current* Professor (Honorary)
Department of Epidemiology and Preventive Medicine
Monash University, Melbourne, Australia

2008- *current* Director, Hand Hygiene Australia
Australian Commission on Safety and Quality in Healthcare
Department of Health & Aging, Canberra

2002- *current* Infectious Diseases Physician
Bendigo Health & Mallee-Loddon Region, Bendigo, Victoria, Australia

Other Appointments:

(Reverse chronological order)

Hospital Appointments:

2013 - *current* Board Member, Otway Health Board of Management, Apollo Bay, Victoria

1996 - 2000 Director, Infectious Disease & Clinical Epidemiology Department
Monash Medical Centre, Clayton, Australia

1992 - 1996 Deputy Director, Infectious Diseases Unit
Microbiology & Infectious Disease Dept, Monash Medical Centre, Clayton, Australia

1992 - 2004 Consultant Physician in Infectious Disease, Alfred Hospital, Melbourne, Australia

1991 - 1995 Visiting Physician in Infectious Disease, Austin Hospital, Melbourne, Australia

1991 - 1992 Staff Physician, Fairfield Infectious Disease Hospital, Melbourne, Australia

1988 Visiting Physician, Fairfield Infectious Disease Hospital, Melbourne, Australia

Academic Appointments:

1996 - 1999 Clinical Associate Professor, Department of Epidemiology and Preventive Medicine
Monash University, Melbourne, Australia

1992 - 1996 Senior Lecturer (Hon), Department of Medicine
Monash University, Melbourne

1992 - 1996 Senior Lecturer (Hon), Department of Epidemiology and Preventive Medicine
Monash University, Melbourne

1992 - 1996 Senior Lecturer (Hon), Department of Microbiology
Monash University, Melbourne

1992 - 1995 Clinical Instructor, Austin & Repatriation Hospitals Clinical School
University of Melbourne, Melbourne, Australia

1988 Lecturer, Department of Social and Preventive Medicine
Monash University, Melbourne, Australia

Committee Positions & Appointments:

2015 – 2016 Hospital-Acquired Infection Advisory Committee. Department of Health & Human
Services, Victoria, Australia

2012 – 2014 Principal Member, Antibiotic Guidelines Writing Committee, Australian National
Antibiotic Guidelines. *Antibiotic*. Therapeutic Guidelines Limited, Melbourne,
Australia

2010 – 2012 Member, Antimicrobial Resistance Advisory Committee
National Health & Medical Research Council (NHMRC)

2009 – 2012 Chair, Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
Program Committee, American Society For Microbiology

2006 – 2009 Vice-Chair (Chair-elect), Interscience Conference on Antimicrobial Agents &
Chemotherapy (ICAAC) Program Committee, American Society For Microbiology

2006 – 2009 President, Australasian Society for Infectious Diseases

2005 – 2006 Member, ICAAC (Interscience Conference on Antimicrobial Agenst &
Chemotherapy) Program Committee, American Society For Microbiology

2003 – 2006 Vice-President (President-elect), Australasian Society for Infectious Diseases

2003 – 2008 Member, (immediate past-Chair) Specialist Advisory Committee for Infectious
Diseases, Royal Australasian College of Physicians

1997 - 2003 Chairman, Specialist Advisory Committee for Infectious Diseases
Royal Australasian College of Physicians

1997 - 2000 Member, Victorian Infectious Diseases Group (VIDG)
Department of Human Services, Victoria

1997 - 2001 Treasurer, Executive Committee

Australian Home & Outpatient Intravenous Therapy Association (AHOITA)

- 1995 - 2002 Member, Tuberculosis Advisory Committee
Department of Human Services, Victoria
- 1994 - 2000 Director of Physician Training, Monash Medical Centre
Royal Australasian College of Physicians
- 1994 - 2000 Regional Examiner, Examinations Committee
Royal Australasian College of Physicians
- 1992 - 2000 Member, Infection Control Committee
Monash Medical Centre and Southern Health Care Network
- 1992 - 2000 Member, Victorian State Committee
Royal Australasian College of Physicians
- 1998 - 1999 Member, Steering Committee, Centre for Clinical Effectiveness
Monash Medical Centre
- 1997 - 1999 Member, Interim Steering Committee, Institute of Public Health Research
Monash Medical Centre
- 1996 - 1999 Council Member, Australasian Society for Infectious Diseases
- 1991 - 1999 Member, Fairfield Travel Health, Private Travel Consultants, Melbourne
- 1993 - 1998 Member, Board of Graduate Studies, Monash Medical Centre
- 1995 - 1997 Founding Chairman
Australian Home & Outpatient Intravenous Therapy Association, (AHOITA)
- 1994 - 1997 Treasurer, Organising Committee
20th International Congress of Chemotherapy (ICC), Sydney 1997
- 1994 - 1997 Member, Executive Management Committee
Division of Medicine, Monash Medical Centre
- 1993 - 1994 Co-ordinator - House Medical Officer Program
Division of Medicine, Monash Medical Centre
- 1992 - 1994 Member, Quality Assurance Sub-Committee, Monash Medical Centre
- 1992 - 1993 Assistant Honorary Secretary, Victorian State Committee
Royal Australasian College of Physicians
- 1991 - 1992 Member, Victorian State Committee, Australian Faculty of Public Health Medicine
- 1984 President, Resident Medical Officers Society, Prince Henry's Hospital, Melbourne

Editorial Appointments:

- 2007 - *current* Reviewer; Journal: *Lancet Infectious Diseases*
- 2007 - 2010 Member; Advisory Board; Journal: *Journal of Antimicrobial Chemotherapy*
- 2004 - *current* Reviewer; Journal: *Emerging Infectious Diseases*
- 2004 - *current* Member, Editorial Board; Journal: *Clinical Infectious Diseases*
- 2000 - 2014 Member, Editorial Board
Journal: *Antimicrobial Agents and Chemotherapy*, Washington, DC, USA
- 1998 - 2004 Member, Editorial Board
Journal: *Current Treatment Options in Infectious Diseases*; Philadelphia, USA
- 1996 - 2002 Member, Content Review Committee
Journal: *Medical Journal of Australia*
- 1995 - *current* Reviewer. Journal: *Medical Journal of Australia*
- 1991 - *current* Reviewer. Journal: *Clinical Infectious Diseases*; Chicago, USA.
- 1995 - 1997 Editor. "*Central Access*" Newsletter of the Australian Home & Outpatient Intravenous Therapy Association (AHOITA)

Professional Training Appointments:

Fellowship Training:

- 1989-91 Research Fellow in Infectious Disease
New England Deaconess Hospital, Boston, Massachusetts, USA

Clinical & Research Fellow in Infectious Disease
Harvard Medical School, Boston, Massachusetts, USA
- 1988-89 Clinical Fellow in Infectious Disease, New England Deaconess Hospital
Harvard Medical School, Boston, Massachusetts, USA.
- 1987-88 Senior Medical Registrar, Fairfield Infectious Diseases Hospital, Melbourne
- 1986-87 Medical Registrar, Fairfield Infectious Diseases Hospital, Melbourne, Australia
- 1985 Senior Registrar in Infectious Diseases, East Birmingham Hospital,
University of Birmingham, Birmingham, U.K.
Visiting Registrar, Department of Medicine
University of Zimbabwe, Harare, Zimbabwe
- 1984-85 Senior Medical Registrar, Prince Henry's Hospital, Melbourne, Australia

Internship and Residency:

- 1983-84 Medical Registrar, Prince Henry's Hospital, Melbourne, Australia
- 1982-83 Senior Resident Medical Officer, Prince Henry's Hospital, Melbourne, Australia

- 1981-82 Junior Resident Medical Officer, Prince Henry's Hospital, Melbourne, Australia
- 1980-81 Intern, Prince Henry's Hospital, Melbourne, Australia

Overseas Consultancies:

- 2017 Chair, Guidelines Review Committee. “*WHO Guidelines on the Core Components of Infection Prevention and Control Programmes*” and “*Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities*”
Auspice Agency: World Health Organization and World Alliance for Patient Safety
- 2007 - *current* Core Group Member - WHO Guidelines on Hand Hygiene in Health Care. First Global Patient Safety Challenge “*Clean Care is Safer Care*”
Auspice Agency: World Health Organization and World Alliance for Patient Safety
- 2000 Member, CSR/DRS Unit. Development of the WHO Global Strategy for Containment of Antimicrobial Resistance. 6 month sabbatical.
WHO, Geneva, Switzerland
Auspice Agency: World Health Organization
- 1999 Chairman, Writing Committee
WHO Model Prescribing Information: Drugs used in bacterial infections
Geneva, Switzerland
Auspice Agency: World Health Organization
- 1996 WHO Model Prescribing Information: Drugs used in bacterial infections
Geneva, Switzerland
Auspice Agency: World Health Organization
- 1991 Development of a National Policy of Rational Use of Antibiotics
Socialist Republic of Viet Nam
Auspice Agency: World Health Organization

Medical Licensure:

- 1979- *current* Victoria, Australia
- 1985- *current* United Kingdom
- 1988-91 Commonwealth of Massachusetts, USA

Certification:

- 2009 - *current* Fellow, Royal College of Physicians, UK
 2008 - *current* Fellow, Royal College of Physicians of Edinburgh
 1991 - *current* Fellow, Australian Faculty of Public Health Medicine
 1988 - *current* Fellow, Royal Australasian College of Physicians.

Membership in Professional Societies:

- 2009 - *current* Royal College of Physicians, UK
 2009 - *current* Royal College of Physicians of Edinburgh
 2001 - *current* European Society of Clinical Microbiology and Infectious Diseases
 1999 - *current* Australian Society for Antimicrobials
 1997 - *current* British Society for Antimicrobial Chemotherapy
 1995 - 2002 Australian Home & Outpatient Intravenous Therapy Association
 1994 - 2000 Outpatient Intravenous Infusion Therapy Association (OPIVITA), USA
 1994 - *current* Australian Society for HIV Medicine (ASHM)
 1992 - 2005 Australian Society for Microbiology
 1991 - *current* American Society for Microbiology
 1991 - *current* Infectious Diseases Society of America
 1991 - *current* Australasian Society for Infectious Diseases
 1991 - *current* Australian Faculty of Public Health Medicine
 1988 - *current* Royal Australasian College of Physicians.
 1985 - *current* British Medical Council.

Teaching Experience*Undergraduate University Teaching:*

- 2000 - *current* Professor, Department of Medicine
 University of Melbourne, Melbourne, Australia
- 1999 - *current* Professor (Honorary)
 Department of Epidemiology and Preventive Medicine
 Monash University, Melbourne, Australia
- 1997 - 2000 Co-ordinator, 5th year Infectious Diseases “Problem-based” Teaching Program,
 Department of Medicine, Monash University
- 1993 - 2000 Lecturer, Infectious Diseases Teaching Programs in years 2, 4, 5 and 6 Medicine,
 Departments of Medicine & Microbiology, Monash University
- 1993 - 2000 Co-ordinator, Infectious Diseases Vaccination Program,
 1st year Medicine and Nursing, Faculty of Medicine, Monash University
- 1996 - 1999 Clinical Associate Professor
 Department of Epidemiology and Preventive Medicine
 Monash University, Melbourne, Australia
- 1992 - 1995 Clinical Instructor, Infectious Diseases Teaching Program,
 5th and 6th year Medicine, Austin & Repatriation Hospitals Clinical School

University of Melbourne, Melbourne, Australia

1988 Lecturer, 2nd & 3rd year Teaching Program
Department of Social and Preventive Medicine, Monash University.

Post-Graduate University Teaching & Supervision:

- 2015 - 2019 Jason Trubiano, MB BS, FRACP
PhD student
Dept. of Medicine, University of Melbourne
Project: *Antibiotic allergy "de-labelling" in high-risk patients*
- 2013 - current Andrew Mahony, MB BS, FRACP
PhD student
Dept. of Medicine, University of Melbourne
Project: *The origins of VRE and its management/prevention*
- 2012 - 2019 Claire Gordon, MB BS, FRACP
PhD student
Dept. of Medicine, University of Melbourne & Columbia University, NY, USA
Project: *The role of viral infections in transplantation*
- 2010 – 2015 Andrew Stewardson, MB BS, FRACP
PhD student
Department of Medicine, University of Melbourne & University of Geneva, CH
Project: *Antibiotic use in Europe and its role in emergence of multi-drug resistance.*
- 2009 - 2013 James C. Hurley, MB BS, PhD, FRACP
DMedSci student
Department of Medicine, University of Melbourne
Project: *The association of endotoxaemia with Gram-negative bacteraemia*
- 2004 - 2008 Patrick Charles, MB BS, FRACP
PhD student
Department of Medicine, University of Melbourne
Project: *The Australian Community Acquired Pneumonia Study (ACAPS)*
- 1998 - 2005 Alex Padiglione, MB BS, FRACP
PhD student
Department of Epidemiology & Preventive Medicine, Monash University
and Centre for Clinical Effectiveness, Southern Health
Project: *The Melbourne Vancomycin-Resistant Enterococci (VRE) Project*
- 1998 - 2002 Elizabeth A. Grabsch, BSc, Grad Dip Health Admin, Grad Dip Clin Epi.
Master of Public Health
Department of Epidemiology & Preventive Medicine, Monash University
Project: *The assessment of the rate of complications of peripherally inserted central (PIC) and other long term central catheters*
- 1996 - 2000 Rhonda Stuart, MB BS, FRACP
PhD student, Department of Epidemiology & Preventive Medicine,

Monash University
Project: *The Melbourne Mantoux Study*

1995 - 1996 Jillian Bennett. Master of Public Health student,
Department of Epidemiology & Preventive Medicine, Monash University
Project: "*A survey of Victorian General Practitioners knowledge, practices and understanding of adult immunisation*"

1994 Ms Phillipa Connors, BSc (Microbiology)
Honours student, Department of Microbiology, Monash University.
In collaboration with A/Prof. J. Turnidge
Project: *Antibiotic resistance among enterococci in Australia*

Other Post-Graduate Teaching:

1992 - 1998 Lecturer, Annual Travel Health Advice Seminar to General Practitioners
Fairfield Travel Health in conjunction with
Victorian Medical Postgraduate Foundation (VMPF)

1987 - 1996 Occasional Lecturer, Post-graduate Update Program for Pharmacists
Pharmacy Society of Australia

Royal Australasian College of Physicians:

Advanced Physician Training:

1997 - 2003 Chairman,
Specialist Advisory Committee for Infectious Diseases
Royal Australasian College of Physicians

Basic Physician Training:

1994 - 2000 Director of Physician Training, Monash Medical Centre
Royal Australasian College of Physicians

1994 - 2000 Regional Examiner, RACP Examinations Committee
Royal Australasian College of Physicians

Overseas Post-Graduate Teaching Experience:

1999 - 2000 HIV-NAT HIV Medicine Symposium, Thailand
Annula collaborative teaching program between: Chulalongkorn University Medical
School, Bangkok; Netherlands-Australia-Thailand HIV Collaborative;
Monash Medical Centre, Melbourne and Harvard Medical School, Boston.
Funded by Netherlands-Australia-Thailand HIV Collaborative

1992 - 1998 HIV infection in Thailand: Training program in health care worker education
Collaborative teaching program between: Chulalongkorn University Medical School, Bangkok; Monash Medical Centre, Melbourne and Harvard Medical School, Boston.
Funded by World AIDS Foundation

Research Grants

1992-1994	Training Program in HIV education for health care workers in Thailand S. Hammer, P.I.; C. Wanke, C-I; Harvard Medical School <u>M.L. Grayson</u> , C-I; Monash Medical Centre P. Phanuphak, P.I.; Chulalongkorn University Medical School, Bangkok, Thailand Funding: World AIDS Foundation Grant	\$US 60,000
1992-1996	Efficacy of zidovudine for symptomatic HIV infection in Bangkok: "A randomized, open-label, dose-regimen comparison trial of zidovudine in HIV-infected Thai adults with early symptomatic disease." S. Hammer, P.I.; C. Wanke, C-I; Harvard Medical School <u>M.L. Grayson</u> , C-I; Monash Medical Centre P. Phanuphak, P.I.; Chulalongkorn University Medical School, Bangkok, Thailand Funding: Burroughs Wellcome Co. - gratis zidovudine for 200 patients	
1992-1994	The safety, efficacy and cost-effectiveness of home intravenous antibiotic therapy in Australia and its role in the era of Case-mix <u>M.L. Grayson</u> , P.I. Funding: Monash Medical Centre	\$A100,000
1993-1994	Clinical trial of Biapenem in soft tissue infections <u>M.L. Grayson</u> , P.I. Funding: Cyanamid Corporation (Lederle), USA	\$A 57,000
1994	Glaxo Award for Advanced Research in Infectious Diseases <u>M.L. Grayson</u> Funding: Australasian Society of Infectious Disease	\$A 4,000
1994-1996	Hospital-in-the-Home IV Antibiotic Program <u>M.L. Grayson</u> , P.I. Funding: Department of Health & Community Services, Victoria	\$A 280,000
1994-2001	HIV infection in Thailand: training program in health care worker education S. Hammer, P.I.; C. Wanke, C-I; Harvard Medical School <u>M.L. Grayson</u> , C-I; Monash Medical Centre P. Phanuphak, P.I.; Chulalongkorn University Medical School, Bangkok, Thailand Funding: World AIDS Foundation Grant	\$US 40,000
1996-1998	1. An evaluation of the use of the Human Gamma Interferon assay during therapy for tuberculosis 2. An evaluation of the use of the Human Gamma Interferon assay during isoniazid therapy for tuberculosis chemoprophylaxis <u>M.L. Grayson</u> , PI; R. Stuart, Monash Medical Centre & Dept. of Epidemiology & Preventive Medicine, Monash University Funding: CSL Limited, Victoria	\$A 22,500

- 1997-1999 *The Melbourne Mantoux Study*
M.L. Grayson, PI; R. Stuart, Infectious Diseases & Clinical Epidemiology Dept.,
 Monash Medical Centre & Dept. of Epidemiology & Preventive Medicine,
 Monash University
 Funding: Department of Human Services, Victoria \$A 200,000
- 1997-1998 An evaluation of the use of the Human Gamma Interferon assay, using the antigens
 ESAT-6 and MPT-64, to distinguish BCG from tuberculosis infection
 P. Johnson, PI, R. Stuart, CI, M.L. Grayson, CI
 Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre
 Funding: CSL Limited, Victoria \$A 5,592
- 1997-1998 Proposal to address potential infectious disease issues related to re-use of cardiac
 electrophysiological catheters: Part A - Bacteriological studies.
M.L. Grayson (P.I.), E. Grabsch, P. Johnson, J. Smolich, J.J. McNeil.
 Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre,
 Epidemiology and Preventive Medicine Department, Monash University
 Funding: Australian Health Ministers' Advisory Council \$A 46,750
- 1997-2000 Development of Victorian Disease-Specific Guidelines for Hospital in the Home
 (HITH)
M.L. Grayson, PI; M. Montalto, CI, M. McDonald, CI et al.
 Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre;
 Hospital in the Home Units, Frankston Hospital and Geelong Hospital
 Funding: Department of Human Services, Victoria \$A 258,600
- 1997-2000 Assessment of the rate of complications of peripherally-inserted central (PIC)
 catheters - establishing a national surveillance program
M.L. Grayson, PI.
 Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre.
 Funding: Department of Human Services, Victoria \$A 52,000
- 1997-1998 Centre for Clinical Effectiveness, Southern Healthcare Network
 and *The Melbourne VRE Study*
 Public Health Grants Program 1997
 S. Allen, J. Anderson, M.L. Grayson
 Funding: Department of Human Services, Victoria \$A 275,000
- 1998-1999 *The Melbourne VRE Study*
M.L. Grayson, PI; A. Padiglione, D. Spelman, B. Mayall.
 Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre &
 Dept. of Epidemiology & Preventive Medicine, Monash University
 Funding: Department of Human Services, Victoria \$A 75,000
- 1999-2000 A randomised, double-blind trial comparing once-daily i.v. cefazolin + probenecid to
 once-daily i.v. ceftriaxone + placebo for the hospital-in-the-home (HITH) treatment
 of cellulitis
M.L. Grayson, PI; M. McDonald, CI *et al.* Infectious Diseases & Clinical
 Epidemiology Dept., Monash Medical Centre, Geelong Hospital & Dept. of
 Epidemiology & Preventive Medicine, Monash University
 Funding: Department of Human Services, Victoria \$A 117,900

1999-2000	Development of a Monash-Gippsland Hospital-in-the-Home (HITH) Collaborative Network <u>M.L. Grayson</u> , PI; F. Chambers, G. Traa et al. Infectious Diseases & Clinical Epidemiology Dept., Monash Medical Centre, Warragul Hospital, Bairnsdale Hospital & Dept. of Epidemiology & Preventive Medicine, Monash University Funding: Department of Human Services, Victoria	\$A 235,000
2001-2002	Development of a HITH program for managing patients with liver failure and post-transplant complications HITH Quality Improvement Funding Program 2000-2001 <u>M.L. Grayson</u> , PI, Angus P, Jones R, Fithall H. Funding: Department of Human Services, Victoria	\$A 31,250
2001-2002	Development of a Victorian HITH Quality Outcomes Assessment Model HITH Quality Improvement Funding Program 2000-2001 <u>M.L. Grayson</u> , PI, Fithall H. Funding: Department of Human Services, Victoria	\$A 188,250
2001-2003	Implementation and analysis of an intensive multi-site Hand Hygiene Program Program Grant. Quality Improvement Funding Program 2001 <u>M.L. Grayson</u> , PI, Johnson PDR, Mayall B, Martin R, Grabsch EA. Funding: Department of Human Services, Victoria	\$A 583,600
2001-2002	Defining the nosocomial risk and best management of VRE-colonised Outpatients Project Grant. Quality Improvement Funding Program 2001 <u>M.L. Grayson</u> , PI, Johnson PDR, Mayall B, Martin R, Grabsch EA. Funding: Department of Human Services, Victoria	\$A 158,098
2001-2002	Implementation and assessment of an electronic antibiotic approvals, advice and monitoring system. Project Grant. Quality Improvement Funding Program 2001 Kirsa S, PI, <u>M.L. Grayson</u> , Thomson W. Funding: Department of Human Services, Victoria	\$A 97,855
2003-2006	Achieving sustained improvement in hand hygiene practices in Victoria. Project Grant. Victorian Quality Council <u>M.L. Grayson</u> P.I., Johnson PDR, Martin R. Funding: Victorian Quality Council, Victoria	\$A1,947,650
2004-2005	Towards reducing resistance and haematological toxicity of linezolid. National Health & Medical Research Council (NHMRC) Project Grant 284347. Grant advisory group Category 6. CR Rayner (CIA), RL Nation (AIA), <u>ML Grayson</u> (AIB), D Spelman (AIC), M Bailey (AID), P Ward (AIE).	\$A133,513
2006-2007	Statewide roll-out – Improving Hand Hygiene Program Project Grant. Victorian Quality Council <u>M.L. Grayson</u> P.I., Johnson PDR, Martin R. Funding: Victorian Quality Council, Victoria	\$A190,000
2006	Are routine healthcare worker hand hygiene protocols	\$A99,950

(soap/water, alcohol-based hand rub) effective against influenza?.

National Health & Medical Research Council (NHMRC Project Grant 801470).

M.L. Grayson (CIA), P.D.R. Johnson (CIB), C. Birch (CIC), D. Druce (CID).

2008-2011	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A3,600,000
2009-2011	Swine influenza: epidemiology and virology of the Victorian epidemic. National Health & Medical Research Council (NHMRC Project Grant 628976). J. Torresi (CIA), <u>M.L. Grayson</u> (CIB), P.D.R. Johnson (CIC), A. Cheng (CID), C. Aboltins (CIE), I. Barr (CIF).	\$490,000
2011-2012	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A1,200,000
2012-2013	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A800,000
2013-2015	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A1,200,000
2014-2016	Statewide implementation – Infection Control “toolkit” - to enhance electronic hand hygiene auditing and provide rapid outbreak alert system. Victorian Department of Health, Victoria <u>M.L. Grayson</u> (CIA), A. Stewardson (CIB), Austin Health	\$A500,000
2015-2016	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A1,250,000
2016-2018	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$A1,282,447
2017-2019	“Controlling Superbugs” Flagship. Melbourne Genomics Alliance, Melbourne, VIC <u>M.L. Grayson</u> (Flagship Leader), Austin Health	\$A1,009,000
2018-2019	National Hand Hygiene Initiative. Australian Commission for Safety & Quality in Healthcare. <u>M.L. Grayson</u> (CIA), Austin Health	\$591,743
	<u>TOTAL (approx.):</u>	<u>A\$ 17,241,952</u>

Patents

Patent Ref: RS:P49134.AU.1

Patent Application No. 2006235798. Inventors: Grayson, ML; Shilson AD; Kirsa SW.2002

Topical composition – “*DeBug*” alcohol-based handrub solution

Publications

Articles - peer reviewed:

(in temporal order)

1. Phillips P, Grayson ML, Stockman K, Hansky J. Transfusion-related Pseudomonas sepsis. Lancet 1984; 2:879.
2. Grayson ML, Newton-John H. Smoking and Varicella Pneumonia. J Infect 1988; 16(3):312.
3. Grayson ML, Yung AP, Doherty RR. Severe dapsone syndrome due to weekly Maloprim. Lancet 1988; 1:531.
4. Yung AP, Grayson ML. Psittacosis - A Review of 135 Cases. Med J Aust 1988; 148:228-233.
5. Grayson ML, McNeil JJ. Preventive health advice for Australian travellers to Bali. Med J Aust 1988; 149:462-466.
6. Grayson ML, Tee W, Dwyer B. Gastroenteritis associated with *Campylobacter cinaedi*. Med J Aust 1989;150:214-215.
7. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of *Campylobacter pylori* to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8:888-889.
8. Grayson ML, McNeil JJ, Lucas CR. Economic and educational status of zidovudine recipients in Melbourne. Med J Aust 1990; 152:49-50.
9. Hoy J, Mijch AM, Sandland AM, Grayson ML, Lucas CR, Dwyer BW. Quadruple therapy for *Mycobacterium avium-intracellulare* bacteremia in AIDS patients. J Infect Dis 1990; 161:801-805.
10. Grayson ML, Eliopoulos GM. Antimicrobial resistance in the intensive care unit. Sem Resp Infect 1990; 5:204-214.
11. Eliopoulos GM, Klimm K, Grayson ML. *In vitro* activity of Sparfloxacin (AT-4140), a new quinolone antimicrobial. Diag Micro Infect Dis 1990; 13:345-348.
12. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, Yao JDC, DeAngelis DV, Walton L, Wooley JL, Moellering RC Jr. Failure of trimethoprim-sulfamethoxazole in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34:1792-1794.
13. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, Klimm K, Sapico FL, Bayer AS, Moellering RC Jr. Comparison of *Enterococcus raffinosus* with *Enterococcus avium* based on penicillin susceptibility, penicillin-binding protein analysis and high-level aminoglycoside resistance. Antimicrob Agents Chemother 1991; 35:1408-1412.
14. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC, Jr. Increasing resistance to beta-lactam antibiotics among clinical isolates of

Enterococcus faecium : a 22 year review at one institution. *Antimicrob Agents Chemother* 1991; 35:2180-2184.

15. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS. Treatment of experimental enterococcal endocarditis caused by penicillin-resistant enterococci. *Antimicrob Agents Chemother* 1992; 36:1864-1869.
16. Munckhof W, Jones R, Tosolini FA, Marzec A, Angus P, Grayson ML. Liposomal amphotericin therapy and cure of *Rhizopus* sinusitis in a liver transplant recipient. *Clin. Infect. Dis.* 1993; 16:183.
17. Turnidge J, Grayson ML. Optimum treatment of staphylococcal infections. *Drugs* 1993; 45:353-366.
18. Oman K, Grayson ML, Turnidge J. HIV in the suburbs. *Med. J. Aust.* 1993; 158:575.
19. Oman K, Grayson ML, Turnidge J. HIV in the suburbs [reply]. *Med. J. Aust.* 1993; 159:427.
20. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW. Ampicillin/Sulbactam versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients. *Clin Infect Dis* 1994; 18:683-693.
21. Munckhof WJ, Grayson ML, Susil BJ, Pullar MJ, Turnidge J. Cerebral Sparganosis in an East Timorese Refugee. *Med J Aust* 1994; 161:263-4.
22. Oman KM, Kempster P, Grayson ML. Neurocysticercosis and new-onset seizures in short term travellers to Bali. *Med J Aust* 1994; 161:399.
23. Munckhof WJ, Grayson ML, Turnidge JD. Malaria acquired in Bali. *Med J Aust* 1995; 162:223.
24. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy: a safe and effective alternative to inpatient care. *Med J Aust* 1995; 162:249-253.
25. Grayson ML, Gibbons G, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients *JAMA* 1995; 273:721-723.
26. Eisen D, Russell EG, Tymms M, Roper EJ, Grayson ML, Turnidge J. Random amplified polymorphic DNA and plasmid analysis used in the investigation of an outbreak of multi-resistant *Klebsiella pneumoniae*. *J Clin Micro* 1995; 33:713-717.
27. Grayson ML. Diabetic foot infections: Antimicrobial therapy. *Infect Dis Clinics North America* 1995; 9:143-161.
28. Grayson ML, Braniff KM, Bowden DS, Turnidge J. Breast feeding and the risk of vertical transmission of hepatitis C virus. *Med J Aust* 1995; 163:107.
29. Munckhof WJ, Grayson ML, Turnidge JD. Malaria acquired in Bali [Reply]. *Med J Aust* 1995; 163:111.

30. Stuart R, Turnidge J, Grayson ML. Safety of Imipenem in neonates. *J Ped Infect Dis* 1995; 14:804-5.
31. Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In-vitro inhibition of *Helicobacter pylori* NCTC 11637 by organic acids and lactic acid bacteria. *J Applied Bacteriol* 1995; 79:475-479.
32. Midolo PD, Lambert JR, Bell JM, Turnidge JD, Grayson ML. Susceptibility test medium affects detection of antibiotic resistance in *H. pylori*. *J Gastroenterol Hepatol* 1996; 11 (Suppl 1):A38.
33. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis on the safety and efficacy of aminoglycosides given either once daily or as divided doses. *J Antimicrob Chemother* 1996; 37:645-663.
34. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness comparison of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of lower limb infections in diabetic patients. *Clin Infect Dis*; 1997; 24:57-63.
35. Korman TM, Mijch AM, Bassily R, Grayson ML. Fistula-in-ano: Don't forget tuberculosis. *Med J Aust* 1997; 166(7):387.
36. Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. *J Antimicrob Chemother* 1997; 37:371-381.
37. Korman TM, Grayson ML, Turnidge JD. Polymicrobial septicaemia with *Pseudomonas aeruginosa* and *Streptococcus pyogenes* following traditional tattooing. *J Infect* 1997; 35:203.
38. Korman TM, Turnidge JD, Grayson ML. Neurological complications of Chlamydial infections: Case report and review. *Clin Infect Dis* 1997; 25:847-851.
39. Korman TM, Brodie GN, Grayson ML. Pneumococcal arthritis and monoclonal gammopathy of undetermined significance. *Aust NZ J Med* 1997; 27: 342.
40. Midolo PD, Bell JM, Lambert JR, Turnidge JD, Grayson ML. Antimicrobial resistance testing *Helicobacter pylori*: a comparison of E-test and disk diffusion methods. *Pathology* 1997; 29:411-414.
41. Grayson ML. Editorial: Hospital-in-the-home care: is it worth the hassle? *Med J Aust* 1998; 168:262-263.
42. Leder K, Turnidge JD, Grayson ML. Treatment of cellulitis with twice-daily cefazolin via a home-based program. *Med J Aust* 1998; 169:519-522.
43. Montalto M, Grayson ML. Acceptability of early discharge, hospital at home schemes. Treatments that can safely and acceptably managed at home need to be defined. *BMJ* 1998; 317:1652.
44. Leder K, Turnidge JD, Korman TM, Grayson ML. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. *J Antimicrob Chemother* 1999; 43:113-118.

45. Wanke CA, Cohan D, Thummakul T, Jongwuitiwes S, Grayson ML, Hammer SM, Hanvanich M. Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. *Am J Trop Med & Hyg* 1999; 60:871-874.
46. Grayson ML, Grabsch EA, Johnson PDR, Olden D, Aberline M, Li HY, Hogg G, Abbott M, Kerr P. Outcome of a screening program for vancomycin-resistant enterococci (VRE) in a University Teaching Hospital. *Med J Aust* 1999; 171:133-136
47. Stuart RL, Wilson J, Grayson ML. Isoniazid toxicity in Health Care Workers. *Clin Infect Dis* 1999; 28:895-897.
48. Johnson PDR, Stuart R, Grayson ML, Olden D, Clancy A, Ravn P, Andersen P, Britton WJ, Rothel JS. Tuberculin-purified protein derivative-, MPT-64- and ESAT-6-stimulated gamma interferon responses in medical students before and after *Mycobacterium bovis* BCG vaccination and in patients with tuberculosis. *Clin Diagnostic Lab Immunol*, 1999; 6:934-7.
49. Korman TM, Brodie GN, Grayson ML. Monoclonal gammopathy and septic arthritis. *Aust NZ J Med* 1999; 29:752.
50. Phanuphak P, Grayson ML, Sirivichayakul S, Suwanagool S, Ruxrungtham K, Hanvanich M, Ubolyam S, Hughes MD, Wanke CA, Hammer SM. A Comparison of Two Dosing Regimens of Zidovudine in Thai Adults with Early Symptomatic HIV Infection. *Aust NZ J Med*, 2000; 30:11-20.
51. Pierce AB, Broughton SJ, Johnson PDR, Grayson ML. *Vibrio cholerae* in Victoria. *Med J Aust*, 2000; 172:44-5.
52. Stuart RL, Grayson ML. A review of isoniazid-related hepatotoxicity during chemoprophylaxis. *Aust NZ J Med*, 1999; 29:362-7.
53. Stuart RL, Olden D, Johnson PDR, Forbes A, Bradley PM, Rothel JS, Grayson ML. Effect of anti-tuberculous therapy on the tuberculin interferon- γ response in tuberculin skin test-positive healthcare workers and patients with proven tuberculosis. *Int J Tuberc Lung Dis*, 2000; 4:555-61.
54. Stuart RL, Bennett N, Forbes A, Grayson ML. A paired comparison of TST results using 5 vs 10 TU of tuberculin. *Thorax*, 2000; 55:693-5.
55. Padiglione A, Grabsch EA, Olden D, Hellard M, Sinclair MI, Fairley CK, Grayson ML. Fecal colonization with vancomycin-resistant enterococci in Australia. *J Emerg Infect Dis*, 2000; 6:534-6.
56. Stuart RL, Grayson ML. Health care workers and tuberculosis. *Aust N Z J Med*. 2000 Jun;30(3):367-72.
57. Stinear TP, Olden DC, Johnson PDR, Davies JK, Grayson ML. Enterococcal *vanB* resistance locus in anaerobic bacteria in human faeces. *Lancet* 2001; 357:855-6.
58. Stuart RL, Bennett NJ, Forbes AB, Grayson ML. Assessing the risk of tuberculosis infection among healthcare workers: the Melbourne Mantoux Study. Melbourne Mantoux Study Group. *Med J Aust*. 2001; 174:569-73.

59. Ward PB, Johnson PDR, Grabsch EA, Mayall BC, Grayson ML. Treatment failure due to methicillin-resistant *Staphylococcus aureus* (MRSA) with reduced susceptibility to vancomycin. *Med J Aust* 2001; 175:480-483.
60. Padiglione A, Grabsch EA, Wolfe R, Gibson K, Grayson ML. The incidence of fecal colonisation with vancomycin-resistant enterococci (VRE) among residents of Australian long-term care facilities. *Infect Control Hospital Epidemiol* 2001; 22:576-578.
61. Grayson ML, Wesselingh S. Management of infectious diseases. *Med J Aust* 2002; 176:202-3.
62. Grabsch EA, Grayson ML, Johnson PDR, Yates LA, Harper RW, Smolich JJ. Bactericidal efficacy of sterilizing protocol for re-used cardiac electrophysiology catheters. *Am J Cardiol* 2002; 89:770-2.
63. Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, Chambers F. Once-daily IV cefazolin 2gms + oral probenecid 1g is equivalent to once-daily IV ceftriaxone 1gm + oral placebo for the treatment of moderate-severe cellulitis in adults. *Clin Infect Dis* 2002; 34:1440-8.
64. Howden BP, Grayson ML. Hospital-in-the-home treatment of infectious diseases. *Med J Aust* 2002; 176:440-5.
65. Grayson ML. The difference between biological warfare and bioterrorism: Australia finally makes a start towards real preparedness for bioterrorism. *Intern Med J* 2003; 33:213-4.
66. Padiglione A, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, Spelman D, Mayall B, Johnson PDR, Grayson ML. Risk factors for the new detection of vancomycin-resistant enterococci (VRE) in acute-care hospitals that employ strict infection control procedures. *Antimicrob Agents Chemother* 2003;47:2492-8.
67. Charles PGP, Angus PW, Sasadeusz JJ, Grayson ML. Managing healthcare workers following occupational exposure to hepatitis C virus. *Med J Aust* 2003; 179:153-7.
68. Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate *Staphylococcus aureus*. *Clin Infect Dis* 2004; 38:448-451.
69. Howden BP, Ward PB, Charles P, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PDR, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by *Staphylococcus aureus* with reduced vancomycin susceptibility. *Clin Infect Dis* 2004; 38:521-8.
70. Grayson ML, Melvani S, Kirsa SW, Cheung S, Korman AM, Garrett MK, Thomson WA. Impact of an electronic antibiotic advice and approval system on antibiotic prescribing in an Australian teaching hospital. *Med J Aust*. 2004; 180:455-8.
71. Charles PGP, Angus PW, Sasadeusz JJ, Grayson ML. Management of healthcare workers after occupational exposure to hepatitis C virus. *Med J Aust* 2004; 180:196.

72. Charles PG, Ananda-Rajah M, Johnson PD, Grayson ML. Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)? *Med J Aust*. 2004;181:515.
73. Howden BP, Johnson PDR, Charles PGP, Grayson ML. Failure of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* infections. *Clin Infect Dis* 2004; 39:1544.
74. Charles PGP, Grayson ML. The dearth of new antibiotic development: why we should be worried and what can we do about it. *Med J Aust* 2004; 181:549-553.
75. Ballard SA, Grabsch EA, Johnson PDR, Grayson ML. Comparison of three PCR primer sets for the identification of *vanB* gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by *vanB*-containing anaerobic bacilli. *Antimicrob Agents Chemother* 2005; 49:77-81.
76. Howden BP, Vaddadi G, Manitta J, Grayson ML. Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area. *Med J Aust* 2005; 182:186-8.
77. Ballard SA, Pertile KK, Lim M, Johnson PDR, Grayson ML. Molecular characterization of *vanB* elements in naturally-occurring gut anaerobes. *Antimicrob Agents Chemother* 2005; 49:1688-94.
78. Howden BP, Ward PB, Johnson PDR, Charles PGP, Grayson ML. Low-level vancomycin resistance in *Staphylococcus aureus* - an Australian perspective. *Eur J Clin Microbiol Infect Dis*. 2005; 24:100-8.
79. Burrell LJ, Grabsch EA, Padiglione A, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. *Med J Aust*. 2005;182:492..
80. Grabsch EA, Burrell LJ, Padiglione A, O’Keeffe JM, Ballard S, Grayson ML. Defining the risk of environmental & health-care worker contamination with vancomycin-resistant enterococci (VRE) during outpatient procedures & hemodialysis by currently- & previously-colonised patients. *Infect Control Hosp Epidemiol* 2006; 27:287-93.
81. Korman TM, Grayson ML, Turnidge JD. Infectious complications of traditional Samoan tattooing. *J Infect*, 2005; 51:259-60.
82. Charles PGP, Howden BP, Ward PB, Bishop E, Johnson PDR, Grayson ML. Accurate assessment of hVISA nasal carriage. *Clin Infect Dis* 2005; 41:1071-2.
83. Brown TL, Burrell LJ, Edmonds D, Martin R, O’Keeffe J, Johnson PDR, Grayson ML. Hand-hygiene: a standardised tool for assessing compliance. *Aust Infect Control* 2005; 10:51-58.
84. Graham M, Nixon R, Burrell LJ, Bolger C, Johnson PDR, Grayson ML. Low rates of cutaneous reactions to alcohol-chlorhexidine hand hygiene solution during prolonged use in a large teaching hospital. *Antimicrob Agents Chemother* 2005; 49: 4404–4405.
85. Johnson PDR, Martin R, Burrell LJ, Grabsch EA, Kirsa SW, O’Keeffe J, Mayall BC, Edmonds D, Barr W, Bolger C, Naidoo H, Grayson ML. Efficacy of an alcohol/chlorhexidine hand hygiene program in a University teaching hospital with high rates of nosocomial

- methicillin-resistant *Staphylococcus aureus* (MRSA) infections. *Med J Aust* 2005; 183:509-514.
86. Howden BP, Grabsch EA, King H, Graham M, Johnson PDR, Korman TM, Grayson ML, Mayall BC. Community and health-care associated non-multi-resistant methicillin-resistant *Staphylococcus aureus* in Victoria. *Med J Aust* 2005; 183: 548.
 87. Howden BP, Charles PGP, Johnson PDR, Grayson ML. Improved outcomes with linezolid for methicillin-resistant *Staphylococcus aureus* infections: better drug, or reduced vancomycin susceptibility? *Antimicrob Agents Chemother* 2005; 49:4816.
 88. Howden BP, Grayson ML. Dumb and Dumber – the potential waste of a useful anti-staphylococcal agent. Emerging fusidic acid resistance in *Staphylococcus aureus*. *Clin Infect Dis* 2006; 42:394-400.
 89. Launay A, Ballard SA, Johnson PDR, Grayson ML, Lambert T. Transfer of vancomycin resistance transposon Tn1549 from *Clostridium symbiosum* to *Enterococcus* spp. in the gut of gnotobiotic mice. *Antimicrob Agents Chemother* 2006; 50:1054-62.
 90. Bishop E, Melvani S, Howden BP, Charles PGP, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. *Antimicrob Agents Chemother* 2006; 50:1599-1602.
 91. Collignon PJ, Wilkinson IJ, Gilbert GL, Grayson ML, Whitby RM. Healthcare associated *Staphylococcus aureus* blood stream infections – a clinical quality indicator for all hospitals. *Med J Aust* 2006; 184 (8): 404-406..
 92. Charles GP, Johnson PDR, Grayson ML. Conundrums in community-acquired pneumonia. *Med J Aust* 2006; 185:131-2.
 93. Bishop EJ, Grabsch EA, Ballard SA, Mayall B, Xie S, Martin R, Grayson ML. Concurrent analysis of nose and groin swab specimens by the IDI-MRSA PCR assay is comparable to analysis by individual-specimen PCR and routine culture assays for detection of colonization by methicillin-resistant *Staphylococcus aureus*. *J Clin Micro*. 2006; 44:2904-8.
 94. Charles PGP, Johnson PDR, Grayson ML. Still awaiting a useful tool for predicting severe CAP. *Thorax* 2006; 61:1098
 95. Grayson ML. The treatment triangle for Staphylococcal infections. *N Engl J Med* 2006; 355: 724-7.
 96. Denholm J, Horne K, McMahon J, Grayson ML, Johnson PDR. Yoghurt consumption and damaged colonic mucosa: A case of *Lactococcus lactis* liver abscess in an immunocompetent patient. *Scand J Infect Dis* 2006; 38:739-741.
 97. Young HL, Ballard SA, Roffey P, Grayson ML. Direct detection of *vanB2* using the Roche LightCycler *vanA/B* detection assay to indicate vancomycin-resistant enterococcal carriage – sensitive but not specific. *J Antimicrob Chemother* 2007; 59:809-10.
 98. Brown TL, Gamon S, Tester P, Martin R, Hosking K, Bowkett GC, Gerostamoulos D, Grayson ML. Can Alcohol-based Hand-rub Solutions cause you to lose your driver's licence?

- Comparative cutaneous absorption of various alcohols. *Antimicrob Agents Chemother* 2007; 51:1107-8..
99. Dendle C, Mulvy S, Pyrlis F, Grayson ML, Johnson PDR. Severe complications of a “Brazilian” bikini wax. *Clin Infect Dis* 2007; 45:e29-31.
 100. Charles PGP, Grayson ML. Point of care tests for lower respiratory tract infections. *Med J Aust* 2007; 187:36-39.
 101. Walton AL, Howden BP, Grayson ML, Korman TM. Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens. *Intern J of Antimicrob Chemother* 2007; 29: 544-548.
 102. Ananda-Rajah MR, Charles PGP, Melvani S, Burrell LL, Johnson PDR, Grayson ML. Comparing the pneumonia severity index with CURB-65 in patients with community-acquired pneumonia. *Scand J Infect Dis.* 2007:1-8.
 103. Swaminathan A, Martin R, Gamon S, Aboltins C, Athan E, Braitberg G, Catton M, Cooley L, Dwyer D, Edmonds D, Eisen D, Hosking K, Hughes A, Johnson PDR, McLeod A, O’Reilly M, Peters E, Stuart RL, Moran R, Grayson ML. Quantifying personal protective equipment (PPE) and antiviral use during the initial acute management of suspected human cases of pandemic influenza. *Emerg Infect Dis* 2007; 13:1541-7.
 104. McMahon JH, O’Keeffe JM, The Victorian HITH Outcomes Study Group, Grayson ML. Is Hospital-in-the-Home treatment of bacterial endocarditis safe and effective? *Scand J Infect Dis.* 2008;40:40-3.
 105. Collignon PJ, Grayson ML, Johnson PDR. Methicillin-resistant *Staphylococcus aureus* in hospitals: time for a culture change. *Med J Aust* 2007; 187:4-5.
 106. McMahon JH, Grayson ML. Torsade de pointes in a patient receiving fluconazole for cerebral cryptococcosis. *Am J Health Sys Pharm.* 2008; 65(7):619-23.
 107. Chua K, Gürtler V, Montgomery J, Mayall BC, Grayson ML. *Campylobacter insulaenigrae* causing septicemia and enteritis. *J Med Microbiol.* 2007; 56:1565-1567.
 108. Waterer GW, Grayson ML. The United States guidelines for the management of community-acquired pneumonia and their relevance to Australasia. *Intern Med J* 2007; 37:789-91.
 109. Graham M, Ballard SA, Grabsch EA, Johnson PDR, Grayson ML. High rates of fecal carriage with non-enterococcal *vanB* - evidence for an age-related increase between children and adults. *Antimicrob Agents Chemother* 2008; 52:1195-1197.
 110. Charles PGP, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJP, Mayall BC, Armstrong JG, Catton MG, Nimmo GR, Johnson B, Hooy M, the ACAPS Collaboration, Grayson ML. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. *Clin Infect Dis* 2008; 46:1513-21.
 111. Charles PGP, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJP, Mayall BC, Armstrong JG, Korman TM, Holmes PW, Obrosky DS, Peyrani P, Johnson B, Hooy M, the ACAPS Collaboration, Grayson ML.

SMART-COP: a tool for predicting intensive respiratory or inotropic support in community-acquired pneumonia. *Clin Infect Dis* 2008; 47:375-84.

112. Charles PG, Wolfe R, Grayson ML. Reply to Chalmers and Hill. *Clin Infect Dis* 2008; 47:1364.
113. Grayson ML, Jarvie LJ, Martin R, Johnson PD, Jodoin ME, McMullan C, Gregory RH, Bellis K, Cunnington K, Wilson FL, Quin D, Kelly AM; Hand Hygiene Study Group and Hand Hygiene Statewide Roll-out Group, Victorian Quality Council. Significant reductions in methicillin-resistant *Staphylococcus aureus* bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. *Med J Aust*. 2008;188:633-40.
114. Grabsch EA, Chua K, Xie S, Byrne J, Ballard SA, Ward PB, Grayson ML. Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by E-test using oxgall supplementation. *J Clin Microbiol* 2008; 46:1961-4.
115. Grayson ML, Melvani S, Druce J, Barr IG, Ballard SA, Johnson PDR, Birch C. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza on the hands of human volunteers. *Clin Infect Dis* 2009; 2009; 48:285–91.
116. Dendle C, Ballard SA, Grabsch EA, Gao W, Grayson ML. Outbreak of vancomycin resistant *Enterococcus faecium* containing both *vanA* and *vanB* gene clusters. *J Hosp Infect*. 2009; 71 (4):379-381.
117. Domingo MC, Huletsky A, Boissinot M, Hélie MC, Bernal A, Bernard KA, Grayson ML, Picard FJ, Bergeron MG. *Clostridium lavalense* sp. nov., a glycopeptide-resistant species isolated from human faeces. *Int J Syst Evol Microbiol*. 2009; 59(Pt 3):498-503.
118. Charles PG, Davis JS, Grayson ML. Rocket science and the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines for severe community-acquired pneumonia. *Clin Infect Dis*. 2009 48:1796.
119. Johnson D.F, Druce J.D, Birch C, Grayson ML. A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. *Clin Infect Dis* 2009; 49(2):275-7.
120. Horne KC, Howden BP, Graham M, Ward PB, Grabsch EA, Xie S, Mayall BC, Johnson PDR, Grayson ML. Prospective comparison of the clinical pathogenicity of heterogeneous vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* (hVISA/VISA) and vancomycin-susceptible MRSA. *Antimicrob Agents Chemother*. 2009; 53:3447-52.
121. Grayson ML, Johnson PD. Australia's influenza containment plan and the swine flu epidemic in Victoria. *Med J Aust*. 2009; 191:150.
122. Kelley PG, Grabsch EA, Howden BP, Gao W, Grayson ML. Comparison of the Xpert™ MRSA Assay, BD GeneOhm™ MRSA Assay and Culture for the Detection of Nasal and Cutaneous Groin Colonization by Methicillin-Resistant *Staphylococcus aureus* (MRSA). *J Clin Microbiol*. 2009; 47(11):3769-72.

123. Dendle C, Martin RD, Cameron DR, Grabsch EA, Mayall BC, Grayson ML, Johnson PDR. *Staphylococcus aureus* bacteraemia as a quality indicator for hospital infection control. *Med J Aust* 2009; 191: 389-392.
124. Grayson ML, Russo P. The Australian hand hygiene initiative. *Med J Aust* 2009; 191: 420-1.
125. Stewardson A, Grayson ML. Psittacosis. *Infect Dis Clinics Nth America*. 2010; 24(1):7-25.
126. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. *Clin Microbiol Rev*. 2010; 23: 99-139.
127. Gordon CL, Johnson PDR, Permezel M, Holmes NE, Gutteridge G, McDonald CF, Eisen DP, Stewardson AJ, Edington J, Charles PGP, Crinis N, Black MJ, Grayson ML. Association between severe swine-origin influenza A (H₁N₁) virus (S-OIV) infection and immunoglobulin G₂ subclass deficiency. *Clin Infect Dis* 2010; 50(5):672-8.
128. Johnson PDR, Ballard SA, Grabsch EA, Stinear TP, Seemann T, Young HL, Grayson ML, Howden BP. A sustained hospital outbreak of vancomycin-resistant *Enterococcus faecium* bacteremia due to emergence of vanB E. *faecium* sequence type 203. *J Infect Dis*. 2010; 202:1278-86.
129. Gordon CL, Langan K, Charles PGP, Bellomo R, Hart GK, Torresi J, Johnson PDR, Grayson ML. Pooled Human Immunoglobulin therapy in Critically ill patients with Pandemic 2009 Influenza A (H1N1) Pneumonitis and Immunoglobulin G₂ subclass (IgG₂) Deficiency. *Clin Infect Dis* 2011; 52:422-6.
130. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Antimicrobial resistance: Not community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. *Clin Infect Dis*. 2011; 52: 99-114.
131. Moellering RC Jr, Corey GR, Grayson ML. Introduction: fusidic acid enters the United States. *Clin Infect Dis*. 2011; 52 (Suppl 7):S467-8.
132. Grayson ML, Ballard SA, Gao W, Khumra S, Ward P, Johnson PDR, Grabsch EA. Quantitative efficacy of alcohol-based handrub against vancomycin-resistant enterococci (VRE) on the hands of human volunteers. *Infect Control Hosp Epidemiol* 2012; 33: 98-100.
133. Teh B, Olsen K, Black J, Cheng A, Aboltins C, Elliott J, Johnson PDR, Grayson ML, Torresi J. Impact of Swine Influenza and Quarantine Measures on Patients and Households during the H1N1/09 Pandemic. *Scand J Infect Dis* 2012 A; 44:289-96.
134. Grayson ML, Russo PL, Cruickshank M, Bear JL, Gee CA, Hughes C, Johnson PDR, McCann R, McMillan AJ, Mitchell BG, Selvey C, Smith RE, Wilkinson I, on behalf of Hand Hygiene Australia, respective State/Territory contributors and the Australian Commission on Safety and Quality in Healthcare. Outcomes from the first 2 years of the Australian National Hand Hygiene Initiative. *Med J Aust* 2011; 195: 615-9.
135. Tong SYC, Xie S, Richardson LJ, Ballard SA, Dakh F, Grabsch EA, Grayson ML, Howden BP, Johnson PDR, Giffard PM. High-resolution melting genotyping of *Enterococcus faecium*

based on multilocus sequence typing derived single nucleotide polymorphisms. PLoS One. 2011; 6: e29189. Epub 2011 Dec 16

136. Teh B, Grayson ML, Johnson PDR, Charles PGP. Doxycycline versus macrolides in combination therapy for treatment of community-acquired pneumonia. Clin Microbiol Infect 2012; 18: E71–E73.
137. Pulcini C, Bush K, Craig WA, Frimodt-Møller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, Gyssens IC; the ESCMID Study Group for Antibiotic Policies. Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis. 2012; 54:268-274.
138. Gordon CL, Holmes NE, Grayson ML, Torresi J, Johnson PD, Cheng AC, Charles PG. A comparison of immunoglobulin G (IgG) subclass concentrations in severe community-acquired pneumonia and severe Pandemic 2009 Influenza A (H1N1) infection. Clin Vaccine Immunol. 2012; 19:446-8.
139. Lam MM, Seemann T, Bulach DM, Gladman SL, Chen H, Haring V, Moore RJ, Ballard S, Grayson ML, Johnson PD, Howden BP, Stinear TP. Comparative analysis of the first complete *Enterococcus faecium* genome. J Bacteriol. 2012; 194:2334-41.
140. Grayson ML, Charles PG, Howden BP. A potential "blind-spot" in vancomycin treatment studies. Clin Infect Dis 2012; 55:165.
141. Grayson ML, Russo P. Problematic linkage of publicly disclosed hand hygiene compliance and health care-associated *Staphylococcus aureus* bacteraemia rates. Med J Aust 2012; 197:212-4.
142. Grabsch EA, Mahony AA, Cameron DRM, Martin RD, Heland M, Davey P, Petty M, Xie S, Grayson ML. Significant reduction in rates of vancomycin-resistant enterococci (VRE) colonization and disease after introduction of a hospital-wide program of routine bleach-based cleaning. J Hosp Infect 2012; 82:234-42.
143. Mahony AA, Cheng AC, Olsen KL, Aboltins CA, Black JFP, Johnson PDR, Grayson ML, Torresi J. Diagnosing swine 'flu: The inaccuracy of case definitions during the 2009 pandemic, an attempt at refinement, and the implications for future planning. Influenza and Other Respiratory Viruses 2013; 7:403-9.
144. Gardiner BJ, Grayson ML, Wood GM. Inducible resistance to clindamycin in *Staphylococcus aureus*: validation of Vitek-2 against CLSI D-test. Pathology. 2013; 45:181-4.
145. Stuart RL, Cameron D, Scott C, Kotsanas D, Grayson ML, Korman TM, Gillespie E, Johnson PDR. Peripheral Intravenous Catheter-Associated *Staphylococcus aureus* Bacteraemias - More Than Five Years of Prospective Data from Two Tertiary Health Services. Med J Aust. 2013; 198:551-3.
146. Cowan R, Johnson PDR, Urbancic K, Grayson ML. A timely reminder about the concomitant use of fusidic acid with statins. Clin Infect Dis 2013; 57:329-30.
147. Cheah AL, Spelman T, Liew D, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, Kong DC. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect. 2013; 19:E181-9.

148. Holmes NE, Ballard SA, Lam MM, Johnson PD, Grayson ML, Stinear TP, Howden BP. Genomic analysis of teicoplanin resistance emerging during treatment of vanB vancomycin-resistant *Enterococcus faecium* infections in solid organ transplant recipients including donor-derived cases. *J Antimicrob Chemother.* 2013; 68(9):2134-9.
149. Johnson DF, Ratnam I, Matchett E, Earnest-Silveria L, Christiansen D, Leder K, Grayson ML, Torresi J. The incidence of HBV and HCV infection in Australian travelers to Asia. *J Travel Med.* 2013; 20:203-5.
150. Trevillyan J, Angus P, Shelton E, Whitlam J, Ierino F, Pavlovic J, Gregory D, Urbancic K, Torresi J, Testro A, Grayson ML. Electronic estimations of renal function (eGFR) are inaccurate in solid-organ transplant recipients and can result in significant under-dosing of prophylactic valganciclovir. *Antimicrob Agents Chemother* 2013; 57(8):4058-60.
151. Grabsch EA, Xie S, Szczurek PB, Grayson ML, Howden BP. Assessment of the BD GeneOhm MRSA ACP assay using combined swabs for the detection of methicillin resistant *Staphylococcus aureus* (MRSA) colonisation. *Pathology.* 2013; 45:612-3.
152. Howden BP, Holt KE, Lam MM, Seemann T, Ballard S, Coombs GW, Tong SY, Grayson ML, Johnson PD, Stinear TP. Genomic insights to control the emergence of vancomycin-resistant enterococci. *MBio.* 2013; 4(4). doi:pil: e00412-13.
153. Kluytmans J., Price L, Grayson ML, Gottlieb T, Mehtar S, Andreumont A, Wegener HC, Johnson J. Enterobacteria: Ban resistant strains from food chain. *Nature.* 2013; 501(7467):316.
154. Stuart RL, Grayson ML, Johnson PD. Prevention of peripheral intravenous catheter-related bloodstream infections: the need for routine replacement. *Med J Aust.* 2013; 199:751.
155. Lam MM, Seemann T, Tobias NJ, Chen H, Haring V, Moore RJ, Ballard S, Grayson LM, Johnson PD, Howden BP, Stinear TP. Comparative analysis of the complete genome of an epidemic hospital sequence type 203 clone of vancomycin-resistant *Enterococcus faecium*. *BMC Genomics.* 2013 Sep 1;14:595.
156. Chua KYL, Grayson ML, Burgess AN, Lee J, Howden BP. The growing burden of multidrug-resistant infections among returned Australian travellers. *Med J Aust.* 2014; 200:116-8.
157. Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton D, Zeglinski PT, Frauman AG, Grayson ML. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram negative prostatitis? *Clin Infect Dis* 2014; 58:e101-5..
158. Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB. Clinical population pharmacokinetics and toxicodynamics of linezolid. *Antimicrob Agents Chemother.* 2014; 58(4):2334-43.
159. Cheah AL, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, Kong DC. Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia. *BMC Infect Dis.* 2014 Jun 28;14(1):353.

160. Huang GKL, Stewardson AJ, Grayson ML. Back to basics: hand hygiene and isolation. *Curr Opin Infect Dis*. 2014; 27(4):379-89.
161. Stewardson AS, Russo PL, Grayson ML. Doctor, do you have a moment? National Hand Hygiene Initiative compliance in Australian hospitals. *Med J Aust*. 2014; 201:264-5.
162. Cheah AL, Spelman T, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, Kong DC. Impact of vanB vancomycin-resistant enterococcal bacteraemia analysed as a time-varying covariate on length of hospital stay. *Epidemiol Infect*. 2014;142:2667-71.
163. Charles PG, Cheng AC, Grayson ML. It's time to move beyond trying to predict mortality using severity assessment tools in community-acquired pneumonia. *Intern Med J*. 2014; 44:1148.
164. Korman TM, Turnidge JD, Grayson ML. Vancomycin vintage: my favourite DRESS. *Intern Med J*. 2015; 45:233-4.
165. Grayson ML. Response to K. Page *et al.*, Costing the Australian National Hand Hygiene Initiative. *J Hosp Infect*. 2015; 89:137-8.
166. Kwong JC, Grayson ML. TB-HAART trial. *Lancet Infect Dis*. 2015; 15:14-5.
167. Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, Gardiner BJ, Frauman AG. Fosfomycin for treatment of prostatitis: new tricks for old dogs. *Clin Infect Dis* 2015 Oct 1;61(7):1141-3.
168. Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. *J Antimicrob Chemother*. 2015 Jul;70(7):2068-73.
169. Macesic N, Ameratunga M, Grayson ML, Johnson DF. Fever in melanoma: new drugs or bugs? *Clin Microbiol Infect* 2015 Oct;21(10):e77-8.
170. Grayson ML, Macesic N, Huang GK, Bond K, Fletcher, J, Gilbert GL, Gordon DL, Hellsten JF, Iredell J, Keighley C, Stuart RL, Xuereb CS, Cruickshank M. Use of an innovative personality-mindset profiling tool to guide culture-change strategies among different healthcare worker groups. *PLoSOne* 2015 Oct 21;10(10):e0140509.
171. Macesic N, Hall V, Mahony A, Hueston L, Ng G, Macdonell R, Hughes A, Fitt G, Grayson ML. Acute Flaccid Paralysis: The New, The Old, and The Preventable. *Open Forum Infect Dis*. 2015 Dec 9;3(1):ofv190. doi: 10.1093/ofid/ofv190.
172. Grayson ML, Macesic N, Trevillyan J. Reply to Davido and Dinh. *Clin Infect Dis*. 2016;62(5):672.
173. Trubiano J, Chen C, Cheng A, Grayson ML, Slavin M, Thursky K. Antimicrobial Allergy “Labels” Drive Inappropriate Antimicrobial Prescribing – Lessons for Stewardship. *J Antimicrob Chemother* 2016;71(6):1715-22.

174. Goldblatt C, Khumra S, Booth J, Urbancic K, Grayson ML, Trubiano JA. Poor reporting and documentation in drug-associated Steven Johnson syndrome and toxic epidermal necrolysis - lessons for medication safety. *Br J Clin Pharmacol* 2017;83(2):224-226.
175. Grayson ML. Measuring infections in Australia: simple yet frustrating. *Lancet Infect Dis*. 2017; 17(1):9-10.
176. Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, Price L, Egger M, Grayson ML, Kelley E, Allegranzi B; WHO Guidelines Development Group. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. *Antimicrob Resist Infect Control*. 2017;6:6
177. Trubiano JA, Beekmann SE, Worth LJ, Polgreen PM, Thursky KA, Slavin MA, Grayson ML, Phillips EJ. Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. *Open Forum Infect Dis*. 2016;3(3):ofw153.
178. Khumra S, Chan J, Urbancic K, Worland T, Angus P, Jones B, Grayson ML, Trubiano JA. Antibiotic allergy 'labels' in Liver Transplant recipients (ALT) Study. *Antimicrob Agents Chemother*. 2017; 61(5). pii: e00078-17.
179. Stewardson AJ, Stuart RL, Marshall C, Cruickshank M, Grayson ML. More Doctor-Patient Contact Is Not the Only Explanation For Lower Hand-Hygiene Compliance in Australian Emergency Departments. *Infect Control Hosp Epidemiol*. 2017; 38(4):502-504.
180. Buultjens AH, Lam MM, Ballard S, Monk IR, Mahony AA, Grabsch EA, Grayson ML, Pang S, Coombs GW, Robinson JO, Seemann T, Johnson PD, Howden BP, Stinear TP. Evolutionary origins of the emergent ST796 clone of vancomycin resistant *Enterococcus faecium*. *PeerJ*. 2017 Jan 24;5:e2916.
181. Trubiano JA, Thursky KA, Stewardson AJ, Urbancic K, Worth LJ, Jackson C, Stephenson W, Sutherland M, Slavin MA, Grayson ML, Phillips EJ. The impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: A multicentre evaluation. *Clin Infect Dis* 2017 Jul 1;65(1):166-174.
182. Trubiano JA, Stone CA, Grayson ML, Urbancic K, Slavin MA, Thursky KA, Phillips EJ. The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration. *J Allergy Clin Immunol Pract*. 2017 Aug 23. pii: S2213-2198(17)30501-9. doi: 10.1016/j.jaip.2017.06.017.
183. Trubiano JA, Strautins K, Redwood AJ, Pavlos R, Konvinse KC, Aung AK, Slavin MA, Thursky KA, Grayson ML, Phillips EJ. The Combined Utility of Ex vivo IFN- γ Release Enzyme-Linked ImmunoSpot Assay and In vivo Skin Testing in Patients With Antibiotic-Associated Severe Cutaneous Adverse Reactions. *J Allergy Clin Immunol Pract*. 2017 Oct 31. pii: S2213-2198(17)30728-6. doi: 10.1016/j.jaip.2017.09.004. [Epub ahead of print]
184. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outtersson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 2017 Dec 21. pii: S1473-3099(17)30753-3.

185. McLellan JE, Pitcher JI, Ballard SA, Grabsch EA, Bell J, Barton M, Grayson ML. Superbugs in the supermarket? Assessing the rate of contamination with multidrug-resistant Gram-negative bacteria in fresh Australian pork and chicken. *Antimicrob Resis Infect Control* 2018; 7:30. <https://doi.org/10.1186/s13756-018-0322-4>.
186. Trubiano JA, Grayson ML, Thursky KA, Phillips EJ, Slavin MA. How antibiotic allergy labels may be harming our most vulnerable patients. *Med J Aust.* 2018; 208(11):469-470.
187. Trubiano JA, Grayson ML, Phillips EJ, Stewardson AJ, Thursky KA, Slavin MA. Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. *J Antimicrob Chemother.* 2018 Jul 27. doi: 10.1093/jac/dky307.
188. Pidot SJ, Gao W, Buultjens AH, Monk IR, Guerillot R, Carter GP, Lee JYH, Lam MMC, Grayson ML, Ballard SA, Mahony AA, Grabsch EA, Kotsanas D, Korman TM, Coombs GW, Robinson JO, Gonçalves da Silva A, Seemann T, Howden BP, Johnson PDR, Stinear TP. Increasing tolerance of hospital *Enterococcus faecium* to handwash alcohols. *Sci Transl Med.* 2018 Aug 1;10(452). pii: eaar6115.
187. Grayson ML, Stewardson AJ, Russo PL, Ryan KE, Olsen KL, Havers SM, Greig S, Cruickshank M. Effects of the Australian National Hand Hygiene Initiative after 8 years on infection control practices, health-care worker education, and clinical outcomes: a longitudinal study. *Lancet Infect Dis* 2018; Sep 28. pii: S1473-3099(18)30491-2.
188. Khumra S, Mahony AA, Devchand M, Walker ST, Garrett K, Grayson ML, Trubiano JA. Counting the cost of critical antibiotic shortages. *J Antimicrob Chemother.* 2018 Oct 11. doi: 10.1093/jac/dky410.
189. Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, Allegranzi B, Harbarth S. Control of Carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies. *Clin Infect Dis.* 2019 Feb 15;68(5):873-884. doi: 10.1093/cid/ciy752.
190. Devchand M, Kirkpatrick CMJ, Stevenson W, Garrett K, Perera D, Khumra S, Urbancic K, Grayson ML, Trubiano JA. Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention. *J Antimicrob Chemother.* 2019 Jun 1;74(6):1725-1730.
191. Zingg W, Storr J, Park BJ, Jernigan J, Harbarth S, Grayson ML, Tacconelli E, Allegranzi B, Cardo D, Pittet D, and the 2017 Geneva-IPC Think Tank. Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (part 3). *Antimicrob Resist Infect Control* 2019 May 22;8:83.
192. Trubiano JA, Slavin MA, Thursky KA, Grayson ML, Phillips EJ. Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. *J Allergy Clin Immunol Pract.* 2019 Sep - Oct;7(7):2151-2153.
193. Devchand M, Stewardson AJ, Urbancic KF, Khumra S, Mahony AA, Walker S, Garrett K, Grayson ML, Trubiano JA. Outcomes of an electronic medical record (EMR)-driven intensive care unit (ICU)-antimicrobial stewardship (AMS) ward round: Assessing the "Five Moments of Antimicrobial Prescribing". *Infect Control Hosp Epidemiol.* 2019 Oct;40(10):1170-1175.

Submitted publications - currently under review:

--

Articles - non-peer reviewed:

194. Grayson ML. Antibiotics & antibacterials. *Current Therapeutics* 1993; 34(4):19-24.
195. Turnidge J, Grayson ML. Staphylococcal infections. Optimum treatment. *Current Therapeutics* 1993; 34(8):67-75.
196. Korman TM, Grayson ML. Treatment of urinary tract infections. *Australian Family Physician* 1995; 24:2205-22011.
197. Leder K, Grayson ML. Returning from holiday with an illness. *Current Therapeutics* 1998, October, pp 29-39.
198. Grayson ML, Russo PL, Ryan K, Bellis K. Good hand hygiene is good medicine. *Medicine Today* 2012; 13:28-37.

Books & Book Chapters:

1. Grayson ML. Health Advice For Travellers;
Copyright Fairfield Hospital, Melbourne, 1986.
First edition 1986: Book No. ISBN 1-86252-273-1.
Second Edition 1988: Book No. ISBN 0 7316 3080 7
2. The Use of Antibiotics, 5th edition Kucers A, Crowe S, Grayson ML, Hoy J. Butterworth Heinemann Limited. Published August 1997.
Sole authored section: Part II: Synthetic Antibacterial & Antiparasitic Drugs.
23 chapters, pages 805 to 1178.
3. Infections in patients with diabetes. Grayson ML. *In: Infectious Diseases – a clinical approach*. Eds. Yung AP, McDonald MI, Spelman DW, Street AC, Johnson PDR. Cherry Print, Victoria. 2001, p. 330-338.
4. Antibacterial agents. Grayson ML, WJ Spicer. *In: Infectious Diseases – a clinical approach*. Eds. Yung AP, McDonald MI, Spelman DW, Street AC, Johnson PDR. Cherry Print, Victoria. 2001, p. 415-432.
5. Home therapy with antibiotics. Howden BP, Grayson ML. *In: Infectious Diseases, 2nd edition*. Eds: Cohen J, Powderly WG and Berkley SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, Maki DG, McAdam KPWJ, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J. Mosby, 2004, Edinburgh. Chapter 190, p 1757-64.
6. Infections in patients with diabetes. Grayson ML. *In: Infectious Diseases – a clinical approach, 2nd edition*. Eds. Yung AP, McDonald MI, Spelman DW, Street AC, Johnson PDR, Sorrell T, McCormack J. IP Communications, Victoria. 2005, p. 403-410.

7. Antibacterial agents. Grayson ML, WJ Spicer. *In: Infectious Diseases – a clinical approach*, 2nd edition. Eds. Yung AP, McDonald MI, Spelman DW, Street AC, Johnson PDR, Sorrell T, McCormack J. IP Communications, Victoria. 2005, p. 511-531.
8. Kucers' "The Use of Antibiotics", 6th edition
Supervising editor: Grayson ML.
Editors: Crowe S, Grayson ML, McCarthy J, Mills J, Mouton J, Norrby R, Paterson D, Pfaller M. Arnold-Hodder and American Society for Microbiology (ASM). Publication date: 24th Sept. 2010. 258 chapters; 3,000 pages.
9. "Emerging Infections", 9th edition
Editors: Scheld WM, Grayson ML, Hughes JM. American Society for Microbiology. ASM Press, Washington DC, 2010. ISBN 978-1-55581-525-7.
10. "50 years of ICAAC". Editors: Bush K, Craig WA, Dalie J, Delgado A, Edwards MS, Grayson ML, Jacoby G, Miller G, Thornsberry C. American Society for Microbiology. ASM Press, Washington DC, 2010.
11. Kucers' "The Use of Antibiotics", 7th edition 2018
Editor-in-Chief: Grayson ML.
Editors: Cosgrove S, Crowe S, Grayson ML, Hope W, McCarthy J, Mills J, Mouton J, Paterson D. Taylor & Francis, and American Society for Microbiology (ASM). Projected publication date: 2018. 269 chapters; Estimated - 5200 pages.

Invited Presentations & Abstracts

(in temporal order)

1. Grayson ML. Health Advice for Travellers. Pharmacy Society of Australia. Melbourne, Victoria; April 1987.
2. Grayson ML. Psittacosis - A Review of 135 Cases. Combined Meeting of the Australasian Society of Infectious Disease and American Society of Infectious Disease. Perth, Western Australia; Feb. 1987.
3. Lucas CR, Mijch AM, Sandland AM, Grayson ML, Dwyer BW. Evidence that drug therapy may be effective in *Mycobacterium aviu-intracellulare*. (Abstract No. 7534.) In Program and abstracts of the IV International Conference on AIDS. Stockholm. 1988.
4. Grayson ML, Wennersten CB, Eliopoulos GM, Zigelboim-Daum S, Moellering RC. Differentiation of *Enterococcus avium* and *Enterococcus raffinosus* by penicillin susceptibility and penicillin-binding protein (PBP) analysis. (Abstract No. 927) Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta. 1990.
5. Grayson ML, Balogh K, Levin E, Karchmer AW, Diabetic Foot Study Group. "Probing to bone" - a useful clinical sign of osteomyelitis in diabetic fetid feet. (Abstract No. 245) Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta. 1990.
6. Grayson ML, Gibbons GW, Freeman DV, Karchmer AW. A comparison of the outcome of medical vs surgical therapy of pedal osteomyelitis in diabetics. Australasian Society of Infectious Disease Scientific Meeting. Lorne, Australia. 1991.
7. Grayson ML, Wennersten CB, Ruoff KL, Eliopoulos GM, Moellering RC, Jr. Increasing beta-lactam resistance among clinical enterococcal isolates. Australasian Society of Infectious Disease Scientific Meeting. Lorne, Australia. 1991.
8. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC, Jr. Increasing resistance to β -lactam antibiotics among clinical isolates of *Enterococcus faecium*: a 22 year review at one institution. (Abstract 983) Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago. 1991.

9. Grayson ML, Gibbons G, Balogh K, Habershaw G, Levin E, Karchmer AW. Pedal Infections in diabetics: empiric treatment (Rx) with ampicillin/sulbactam (U) vs imipenem/cilastatin (P). (Abstract 957) Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago. 1991.
10. Grayson ML. Clinical Manifestations of HIV infection. World AIDS Foundation & Thai Red Cross Workshop on HIV. Bangkok, Thailand. April 1992.
11. Grayson ML. Presentation and management of opportunistic infections in patients with HIV infection. World AIDS Foundation & Thai Red Cross Workshop on HIV. Chiang Mai & Bangkok, Thailand January 1993.
12. Midolo PD, Luo F, Lambert JR, Hull RR, Grayson ML. *In-vitro* inhibition of *Helicobacter pylori* by organic acids and lactic acid bacteria. Australian Society of Microbiology. Perth 1993. Abstract PO1.2.
13. Luo F, Midolo PD, Lambert JR, Grayson ML, Hull RR. *In vitro* antagonistic activity of lactic acid bacteria against *Helicobacter pylori*. Australian Society of Microbiology. Perth 1993. Abstract PO1.1.
14. Braniff KM, Bowden DS, Locarnini SA, Grayson ML. Lack of evidence of mother-infant transmission of HCV in Victoria. Australian Society of Microbiology. Perth 1993. Abstract P11.6.
15. Grayson ML, Panayotou A, Hicks AM, Aberline MH, Silvers J, Allen PS, Turnidge J. Antibody (Ab) Status of High-Dependency Staff to Common, Potentially Nosocomial, Viral Pathogens. Australian Society of Microbiology. Perth 1993. Abstract PO13.1.
16. Marzec A, Butcher RH, Tosolini FA, Munckhof W, Grayson ML, Angus PW, Jones RM. Rhinocerebral zygomycosis in a liver transplant recipient. XII ISHAM Meeting. Adelaide, 1994
17. Grayson ML, Braniff KM, Allwell L, Bowden DS, Locarnini SA, Turnidge J. The risk of maternal-infant transmission of hepatitis C and breast feeding. Australasian Society of Infectious Disease Scientific Meeting. Canberra. 1994.
18. Munckhof WJ, Grayson ML, Turnidge J. Meta-analysis of once daily aminoglycoside dosing. Australasian Society of Infectious Disease Scientific Meeting. Canberra, 1994.
19. Eisen D, Russell E, Tymms M, Roper E, Grayson ML, Turnidge J. Random amplified polymorphic DNA and plasmid analysis used in the investigation of an outbreak of multi-resistant *Klebsiella pneumoniae*. Australasian Society of Infectious Disease Scientific Meeting. Canberra, Australia. 1994.
20. Grayson ML. Antibiotic resistance among enterococci. Glaxo Award for Advanced Research in Infectious Diseases. Australasian Society of Infectious Disease Scientific Meeting. Canberra, Australia. 1994.
21. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy - a safe and effective alternative to inpatient care. Australasian Society of Infectious Disease Scientific Meeting. Canberra, Australia. 1994.
22. Grayson ML. Update on the presentation and management of opportunistic infections. Clinical Management of HIV Disease. Harvard Medical School, Chulalongkorn Medical School and HIV/AIDS Treatment & Care Consortium of Thailand. 18-22nd April, 1994. Bangkok and Khon Kaen, Thailand.
23. Grayson ML. Controversies in endocarditis treatment: Impact of antibiotic resistance in treatment outcomes. Australian Society of Microbiology. Melbourne 1994. Abstract S18.1.
24. Connors PA, Grayson ML, Olden DC, Franklin C, Spelman D, Turnidge J. Antibiotic resistance among enterococci. Australian Society of Microbiology. Melbourne 1994. Abstract GP.35.
25. Grayson ML, Braniff KM, Allwell L, Bowden DS, Locarnini SA, Turnidge J. The risk of maternal-infant transmission of hepatitis C [HCV] and breast feeding. (Abstract 105, M6) Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando. 1994.
26. Grayson ML. Clinical diagnosis and management of PCP and mycobacterial infections. World AIDS Foundation HIV Medicine Course. Bangkok & Chiang Mai. April, 1995.
27. Grayson ML. Diagnosis and management of CMV infections. World AIDS Foundation HIV Medicine Course. Bangkok & Chiang Mai. April, 1995.

28. Stuart RL, Turnidge J, Grayson ML. Safety of imipenem in neonates. Australasian Society of Infectious Disease Scientific Meeting, Darwin, Australia. 1995.
29. Korman TM, Grayson ML, Turnidge JD. Adverse reactions associated with IV vancomycin therapy. Australasian Society of Infectious Disease Scientific Meeting, Darwin, Australia. 1995. Aust NZ J Med 1995; 25:567.
30. Grayson ML. Home IV Antibiotic Therapy - it's like a play; it's all in the delivery! Australian Home & Outpatient Intravenous Therapy Association Scientific Meeting, Melbourne, 1995
31. Grabsch E, Aberline M, Haines B, Marshall C, Korman TM, Grayson ML, Turnidge JD. Environmental management for the prevention of invasive aspergillosis. In: Program and Abstracts of the Annual Scientific Meeting, Australian Society for Microbiology, Canberra, ACT. Abstract P20.2. Microbiology Australia 1995; 16:84.
32. Stuart R, Turnidge J, Grayson ML. Safety of imipenem in neonates. (Abstract 176) Infectious Diseases Society of America Annual Meeting. San Francisco. 1995.
33. Grayson ML. Approach for fever and weight loss. World AIDS Foundation Training Course in Laboratory Diagnosis of Opportunistic Infections in HIV Infection. Thai Red Cross Program on AIDS/Harvard Medical School/Ministry of Public Health. March 11-15, 1996. Bangkok.
34. Grayson ML. Approach for cough and dyspnea. World AIDS Foundation Training Course in Laboratory Diagnosis of Opportunistic Infections in HIV Infection. Thai Red Cross Program on AIDS/Harvard Medical School/Ministry of Public Health. March 11-15, 1996. Bangkok.
35. Grayson ML. Approach for headache and dementia. World AIDS Foundation Training Course in Laboratory Diagnosis of Opportunistic Infections in HIV Infection. Thai Red Cross Program on AIDS/Harvard Medical School/Ministry of Public Health. March 11-15, 1996. Bangkok.
36. Midolo PD, Lambert JR, Bell JM, Turnidge JD, Grayson ML. Susceptibility test medium affects detection of antibiotic resistance in *H. pylori*. The First Western Pacific Helicobacter Congress. Guangzhou, China. 1996.
37. Stuart RL, Phillipson R, Turnidge J, Grayson ML. Are the current Mantoux testing guidelines in healthcare workers (HCWs) appropriate? Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1996, Broome.
38. Stuart RL, Turnidge J, Grayson ML. Are the current Mantoux testing guidelines in healthcare workers (HCWs) appropriate? Infectious Diseases Society of America Annual Scientific Conference, September 1996, New Orleans, USA.
39. Grayson ML. Cost effectiveness of home IV therapy strategies. Australasian Society for Infectious Diseases. Annual Scientific Meeting, March 1997, Queenstown, NZ.
40. Leder K, Korman T, Turnidge J, Grayson ML. Continuous infusion (C/I) flucloxacillin therapy. Australasian Society for Infectious Diseases. Annual Scientific Meeting, March 1997, Queenstown.
41. Grayson ML. Tuberculosis and the Health Care Worker. 11th International Conference of the Australian Infection Control Association. May 1997. Melbourne. (Abstract 38).
42. Grayson ML. Cost effectiveness of various treatment regimens. Australian Home & Outpatient Intravenous Therapy Association Scientific Meeting and 20th International Congress of Chemotherapy, Sydney, July, 1997
43. Grayson ML. Diabetic foot infections. 20th International Congress of Chemotherapy, Sydney, July, 1997.
44. Grayson ML. Quality - Industry Standards. PATCH III Conference, July 1997 Melbourne.
45. Grayson ML. Pneumocystis pneumonia 1998 Bangkok Symposium on HIV Medicine, Jan. 21-23, 1998. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Program on AIDS, Thai Red Cross Society, and The WHO Collaborating Centre for Training & Research on HIV/AIDS Clinical Management and Counselling.

46. Grayson ML. Mycobacterium Avium Complex (MAC) Infections 1998 Bangkok Symposium on HIV Medicine, Jan. 21-23, 1998. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Program on AIDS, Thai Red Cross Society, and The WHO Collaborating Centre for Training & Research on HIV/AIDS Clinical Management and Counselling.
47. Johnson PDR, Stuart R, Olden D, Rothel J, Clancy A, Grayson ML. Mantoux tests and *Quantiferon-TB* assays performed before and after BCG administration in medical students. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1998, Hobart.
48. Stuart RL, Bennett N, Hart W, Johnson PDR, Grayson ML. Mantoux testing of health care workers (HCWs) - the Melbourne Mantoux Study (MMS). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1998, Hobart.
49. Stuart RL, Wilson J, Grayson ML. Isoniazid toxicity in hospital employees (Hes). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1998, Hobart.
50. Phanuphak P, Grayson ML, Sirivichayakul S, Suwanagool S, Ruxrungtham K, Hanvanich M, Ubolyam S, Hughes MD, Wanke CA, Hammer SM. A comparison of two dosing regimens of zidovudine (ZDV) in Thai adults with early symptomatic HIV infection. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1998, Hobart.
51. Grabsch EA, Johnson PDR, Aberline M, Kerr P, Abbott M, Olden D, Grayson ML. Outcome of a screening program for vancomycin-resistant enterococci (VRE) in a university teaching hospital. Abstract 33. Royal Australasian College of Physicians. Joint Scientific Meeting, May 1998, Melbourne.
52. Grayson ML. New antibiotics and new aspects of old antibiotics (Symposium). Royal Australasian College of Physicians. Joint Scientific Meeting, May 1998, Melbourne.
53. Stuart RL, Bennett N, Johnson PDR, Grayson ML. Mantoux testing of health care workers (HCWs): the Melbourne Mantoux Study (MMS). (Abstract K-142) Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. 1998.
54. Stuart RL, Olden D, Johnson PDR, Forbes A, Bradley PM, Rothel JS, Grayson ML. The effect of anti-tuberculous therapy on the interferon- γ response in tuberculin skin test positive healthcare workers and patients with proven tuberculosis. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1999, Palm Cove.
55. Padiglione A, Olden D, Grabsch E, Johnson PDR, Aberline M, Barr W, Mayall B, Pearson S, Franklin C, Harrington G, Spelman D, Grayson ML, on behalf of the Melbourne VRE Project. The Melbourne VRE Project - interim results. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 1999, Palm Cove.
56. Stuart RL, Bennett N, Grayson ML. A paired comparison of TST results by using 5 vs. 10 TU of tuberculin. (Abstract 751) Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 1999.
57. Padiglione AA, Olden D, Grabsch E, Pearson S, Franklin C, Spelman D, Mayall B, Johnson P, Hogg G, Grayson ML. Low rates of faecal VRE carriage in Australia: results of the Melbourne VRE study. (Abstract 1728) Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 1999.
58. Grabsch EA, Smolich JJ, Yates L, Johnson PDR, Wellington H, McNeil JJ, Harper R, Grayson ML. Bacteriological efficacy of a cleaning protocol for the re-use of cardiac electrophysiology catheters. The Cardiac Society of Australia and New Zealand. Annual Scientific Meeting, May 1999, New Zealand.
59. Grayson ML. Opportunistic infection prophylaxis in the era of HAART. The HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration. 2000 Bangkok Symposium on HIV Medicine. January 2000, Bangkok
60. Grayson ML, Kahn P, Reark J, Macaulay BM, Chambers F. Is hospital-in-the-Home (HITH) cheaper than in-hospital care? Assessing the financial efficiency of HITH care. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2000, Leura.
61. Padiglione A, Grabsch EA, Olden D, Hellard M, Sinclair MI, Fairley CK, Grayson ML. Will nursing homes become the sump of VRE in Australia? – VRE in the general community and long term care facilities. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2000, Leura.

62. Stuart RL, Bennett N, Grayson ML. A paired comparison of TST results by using 5 vs 10 TU of tuberculin. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2000, Leura.
63. Grabsch EA, Smolich JJ, Yates L, Johnson PDR, Wellington H, McNeil JJ, Harper R, Grayson ML. An assessment of the bacteriological efficacy of a cleaning protocol for the re-use of cardiac electrophysiology catheters. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2000, Leura.
64. Grayson ML. Beta-lactam dosing. The long and the short of it. Australian Society for Antimicrobials, Sydney, 2000.
65. Grayson ML, Williams R. International monitoring of antimicrobial resistance. Medicine in the Millenium Conference. Expo 2000, Hannover, Germany, August 2000.
66. Grayson ML. Global strategy for containment of antimicrobial resistance. Malaysian Society of Infectious Diseases & Chemotherapy. Update in Infectious Diseases, Kuala Lumpur, 21-22 October 2000.
67. Grayson ML. Diabetic foot infections. Malaysian Society of Infectious Diseases & Chemotherapy. Update in Infectious Diseases, Kuala Lumpur, 21-22 October 2000.
68. Grayson ML. Challenges in the diagnosis and prevention of nosocomial infections. Malaysian Society of Infectious Diseases & Chemotherapy. Update in Infectious Diseases, Kuala Lumpur, 21-22 October 2000.
69. Grayson ML, Gibson K, McDonald M, Athan E, Munckhof W, Paull P, Chambers F. Once-daily (O/D) IV cefazolin 2g + oral probenecid 1g is equivalent to O/D IV ceftriaxone 1g + placebo for the Hospital-in-the-Home (HITH) treatment of adult cellulitis. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2001, Melbourne.
70. Stinear TP, Olden DC, Johnson PDR, Davies JK, Grayson ML. Anaerobic bacteria in human faeces are a reservoir of enterococcal *vanB* resistance locus. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2001, Melbourne.
71. Grayson ML, Burrell LJ, Grabsch EA, Maher KH, Thornely CS, Padiglione A. High rates of environmental contamination with vancomycin-resistant enterococci (VRE) by VRE-colonised patients who attend for outpatient and radiological procedures. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2002, Barossa Valley, South Australia
72. Grayson ML, Melvani S, Kirsa S, Charles P, Korman TM, Tapley N, Thomson W. Introduction of an Infectious Diseases Electronic Antibiotic Advice & Approval System (IDEA³S). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2002, Barossa Valley, South Australia
73. Grayson ML. Investigation and management of diabetic foot infections. S293. 12th European Congress of Microbiology and Infectious Diseases. Milan, Italy. April 24-27, 2002.
74. Ward PB, Viswanath R, Bakopanus M, Johnson PDR, Mayall B, Grayson ML. Agar dilution screening for hetero-vancomycin resistant *Staphylococcus aureus*. International Symposium on Staphylococci and Staphylococcal Infections (ISSSI), Japan, 2002.
75. Grayson ML. What comprises a resistance management program? 8th Western Pacific Congress on Chemotherapy & Infectious Diseases. Perth, December 1-5th, 2002.
76. Grayson ML. GRE – Local aspects of a global problem. Treatment options. 8th Western Pacific Congress on Chemotherapy & Infectious Diseases. Perth, December 1-5th, 2002.
77. Melvani S, Kirsa S, Cheung S, Jones S, Garrett K, Grayson ML. Use of the Infectious Diseases Electronic Antibiotic Advice & Approval System (IDEA³S) to assess accuracy of Pneumonia Severity Index (PSI) in community acquired pneumonia (CAP). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2003, Canberra, ACT.
78. Grabsch EA, Burrell LJ, Padiglione A, O’Keeffe JM, Xie S, Ballard S, Grayson ML. Dissemination of vancomycin-resistant enterococci (VRE) during outpatient procedures & haemodialysis by currently and previously VRE-colonised patients. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2003, Canberra, ACT.

79. O’Keeffe J, Johnson PDR*, Martin R, Barr W, Grabsch EA, Mayall BC, Kirsa SW, Edmonds D, Benton B, Burrell LJ, Plumley N, Grayson ML. Effective introduction of alcohol/chlorhexidine handrub (DeBug™) in medical, surgical & intensive care units at ARMC. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2003, Canberra, ACT.
80. Grayson ML. Drug approval software. Australian Society for Antimicrobials, Annual Scientific Meeting, May 2003, Melbourne, VIC.
81. Grayson ML, Grabsch EA, Burrell LJ, O’Keeffe JM, Xie S, Ballard S, Padiglione A. Defining the rate of environmental and healthcare worker (HCW) contamination with vancomycin-resistant enterococci (VRE) during outpatient procedures and hemodialysis by currently and previously VRE-colonised patients. (Abstract K-1107) 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September, 2003.
82. Howden BP, Ward PB, Charles P, Grayson ML. Clinical features and treatment outcomes of serious infections due to *Staphylococcus aureus* with reduced susceptibility to vancomycin (SA-RVS) in Australia and New Zealand. (Abstract K-1750) 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September, 2003.
83. Ballard SA, Grabsch EA, Xie S, Johnson PDR, Grayson ML. Correlating the detection of *vanB* genes in faeces to the presence of vancomycin-resistant enterococci (VRE): interference by *vanB* containing anaerobes. (Abstract D-1890) 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September, 2003.
84. Ananda-Rajah M, Burrell LR, Johnson PDR, Grayson ML. A comparison of three pneumonia severity index scoring systems (PSI) for community acquired pneumonia (CAP) to predict aetiology, appropriate antibiotic (ABx) selection and clinical outcomes. Australasian Society for Infectious Diseases. Annual Scientific Meeting, May 2004, Alice Springs, NT.
85. Johnson PDR, Mayall BC, Grabsch EA, Burrell LJ, Bolger C, Martin R, Edmonds D, Barr W, Kirsa SW, Benton B, Howden B, Naidoo H, Grayson ML. Significant reduction in infections with methicillin-resistant *Staphylococcus aureus* (MRSA) following the introduction of the DeBug™ Infection Prevention Program. Australasian Society for Infectious Diseases. Annual Scientific Meeting, May 2004, Alice Springs, NT.
86. Graham M, Nixon R, Burrell LJ, Bolger C, Johnson PDR, Grayson ML. Low rates of cutaneous adverse reactions (CARs) to alcohol-chlorhexidine hand hygiene (HH) solution (DeBug™) in a large teaching hospital. Australasian Society for Infectious Diseases. Annual Scientific Meeting, May 2004, Alice Springs, NT.
87. Howden BP, Ward PB, Xie S, Wang J, Johnson PDR, Charles PGP, Grayson ML. Identification of a new agar dilution screening method for the accurate detection of heterogeneous-vancomycin intermediate *Staphylococcus aureus* (hVISA). (Abstract D-59/132) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. November, 2004.
88. Graham M, Nixon R, Burrell LJ, Bolger C, Johnson PDR, Grayson ML. Low rates of cutaneous adverse reactions (CARs) to alcohol-chlorhexidine hand hygiene (HH) solution (DeBug) in a large Australian teaching hospital. Abstract K-1596/438) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. November, 2004.
89. Bishop E, Melvani S, Howden BP, Charles PGP, Grayson ML. Good clinical outcomes but high rates of adverse reactions (Ars) in seriously ill patients treated with prolonged linezolid (LZD) therapy: Development of a practical management protocol. (Abstract K-1569/404) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. November, 2004.
90. Ballard SA, Pertile KK, Johnson PDR, Grayson ML. Molecular characterization of a *Tn* 5382/1549 element encoding *vanB*, identified in *Clostridia* and other anaerobes. (Abstract C1-950/83) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. November, 2004.
91. Johnson PDR, Mayall BC, Grabsch EA, Burrell LJ, Bolger C, Martin R, Edmonds D, Barr W, Kirsa SW, Benton B, Naidoo H, Ananda-Rajah M, Howden B, Grayson ML. Controlling hyperendemic nosocomial MRSA in an Australian teaching hospital. (Abstract K-1858) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. November, 2004.
92. Ballard SA, Young HL, Grabsch EA, Johnson PDR, Grayson ML. Naturally-occurring *vanB*-containing anaerobes are an important cause of false-positives in the molecular detection of vancomycin-resistant enterococci (VRE). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2005, Busselton, WA.

93. Charles PGP, Whitby M, Fuller A, Holmes P, Christiansen K, Waterer GW, Catton MC, Wright AA, Grayson ML, and the ACAPS Investigators. The aetiology and severity of community-acquired pneumonia (CAP) – early results from the Australian Community-Acquired Pneumonia Study (ACAPS). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2005, Busselton, WA.
94. Bishop E, Melvani S, Howden BP, Charles P, Grayson ML. Clinical outcomes and adverse reactions associated with prolonged linezolid therapy in seriously ill patients. Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2005, Busselton, WA.
95. Grabsch EA, Xie S, Byrne J, Ballard SA, Ward PB, Grayson ML. Oxgall supplement to Mueller-Hinton and brain heart infusion agar improves the routine identification of low-MIC vancomycin-resistant enterococci (LM-VRE). (Abstract D-1652) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. December, 2005.
96. Ward PB, Xie S, Howden BP, Starmans C, Johnson PDR, Grayson ML. Assessment of simple modified agar dilution and disc diffusion methods for the routine detection of hetero-resistant vancomycin-intermediate *Staphylococcus aureus* (hVISA). (Abstract D-1737) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. December, 2005.
97. Melvani S, Cheung S, Garrett M, Korman AM, Charles PGP, Grayson ML. Clinical Impact of the Infectious Diseases Electronic Antibiotic Advice & Approval System (IDEA³S) on Appropriate Antibiotic Prescribing and Rapid Quality Audits. (Abstract W-191) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. December, 2005.
98. Charles PGP, Whitby M, Fuller A, Holmes P, Christiansen K, Waterer GW, Catton M, Wright AA, Grayson ML. Etiology of community-acquired pneumonia (CAP) and usefulness of pneumonia severity assessments for predicting need for ICU admission in Australia. (Abstract L-706) 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. December, 2005.
99. Brown TL, Gamon S, Tester P, Martin R, Hosking K, Bowkett GC, Gerostamoulos D, O'Brien M, Grayson ML. Can alcohol-based hand-rub solutions (ABHRS) cause you to lose your driver's licence? Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2006, Wellington, NZ.
100. Bishop EJ, Grabsch EA, Ballard SA, Mayall B, Xie S, Martin R, Grayson ML. Combined nose & groin swab PCR assay (IDI-MRSA) is comparable to individual specimen PCR & routine culture for detection of colonisation with methicillin-resistant *Staphylococcus aureus* (MRSA). Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2006, Wellington, NZ.
101. McMahon JH, O'Keeffe JM, Grayson ML and The Victorian HITH Outcomes Study Group. Is Hospital-in-the-Home (HITH) treatment of bacterial endocarditis (BE) safe & effective? Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2006, Wellington, NZ.
102. Horne KC, Graham M, Ward P, Howden BP, Xie S, Johnson PDR, Mayall B, Grayson ML. Is there a difference in the pathogenicity & clinical outcomes associated with vancomycin-susceptible *Staphylococcus aureus* (VS-SA) & *S. aureus* with reduced vancomycin susceptibility (RVS-SA)? Australasian Society for Infectious Diseases. Annual Scientific Meeting, April 2006, Wellington, NZ.
103. Brown TL, Gamon S, Tester P, Martin R, Hosking K, Bowkett GC, Gerostamoulos D, O'Brien M, Grayson ML. Can alcohol-based hand-rub solutions (ABHRS) cause you to lose your driver's licence? Assessing the comparative cutaneous absorption of various alcohols. . (Abstract K-1069) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
104. Graham M, Ballard SA, Grabsch EA, Johnson PDR, Grayson ML. Significantly higher rates of non-enterococcal *vanB* carriage in the feces of healthy adults & haemodialysis patients compared to pre-school children. (K-1736) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
105. Horne KC, Graham M, Ward PB, Howden BP, Xie S, Johnson PDR, Mayall B, Grayson ML. Vancomycin-intermediate *Staphylococcus aureus* (hVISA/VISA) & vancomycin-susceptible methicillin-resistant *S. aureus* (VSSA) have similar rates of clinical disease & overall outcomes when assessed prospectively. (Abstract K-785) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.

106. Grabsch EA, Ballard SA, Gao W, Xie S, Holberton J, Watkins AMC, Andersen CC, Ward PB, Bartolo R, Grayson ML. Use of the IDI-MRSA™ Assay in the Management of a Large Outbreak of Hetero-Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) in a Neonatal Intensive Care Unit (NICU). (Abstract D-837) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
107. Charles PGP, Whitby M, Fuller A, Wright AA, Wolfe R, Christiansen K, Waterer GW, Grayson ML. Development of a severity assessment tool for predicting need for ICU admission in patients with community-acquired pneumonia (CAP). (Abstract L-1075) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
108. Boak LM, Rayner CR, Grayson ML, Spelman D, Paterson DL, Melvani S, Capitano B, Forrest A, Li J, Nation RL. Pharmacokinetics (PK) of Linezolid (LZD) in a Typical Patient (pt) Population (pop). (A-1946) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
109. Grayson ML. Treatment of CAP: Mono vs dual therapy – What’s the evidence? (Abstract L-324) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September, 2006.
110. Dendle C, Martin R, Gamon S, Grayson ML, Johnson PDR. Event Surveillance in a Busy Hospital. Australian Society for Infectious Diseases Annual Scientific Meeting, Hobart. March 2007.
111. Charles P, Wolfe R, Whitby M, Fuller A, Wright A, Christiansen K, Waterer G, Grayson ML. Development of a Severity Assessment Tool for Predicting Need for ICU Admission in Patients with Community-Acquired Pneumonia (CAP). Australian Society for Infectious Diseases Annual Scientific Meeting, Hobart. March 2007.
112. Grayson ML, Jarvie L, Wilson F, Hellsten J, Taylor K, Bellis K, Hawkins C, Kelly A. Significant Reductions in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia and Clinical Isolates Associated with a Multi-Site, Hand Hygiene (HH) Culture-Change Program. (K-1374) 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September 2007.
113. Swaminathan A, Grayson ML. Assessing the Quantity of personal Protective Equipment (PPE) and Antivirals Required During the Initial Hospitalisation of Suspected Human Cases of Avian-Pandemic Influenza (API). (K-1781) 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September 2007.
114. Grayson ML, Melvani S, Druce J, Barr I, Ballard SA, Mastorakos T, Johnson PDR, Birch C. Antiviral Efficacy of Soap + Water Handwashing (S+W) and Alcohol-Based Hand-Rub Solutions (ABHRS) against Live H1N1 Influenza A on the Hands of Human Volunteers. (K-1796) 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September 2007.
115. Chaves N, Howden B, Melvani S, Braniff V, Grayson ML. Defining the Optimum Means of Administering Continuous Infusion Penicillin (CIP) – Are Serum Levels Adequate? Australian Society for Infectious Diseases Annual Scientific Meeting, Queensland. April 2008.
116. Kelly PG, Grabsch EA, Howden B, Gao W, Ghaly-Derias S, Grayson ML. Comparison of the GeneXpert Xpert MRSA Assay (GXP-MRSA), BD GeneOhm MRSA Assay (BD-MRSA) & routine Culture for the Detection of Nasal & Cutaneous colonisation with Methicillin-Resistant *Staphylococcus aureus* (MRSA). (D-1138) 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Infectious Diseases Society of America Annual Meeting, Washington. October 2008.
117. Stewardson AJ, Jarvie L, Tullett C, Wilson F, Grayson ML. Comparison of a Simplified Before and After Hand Hygiene (HH) Compliance Tool with a Detailed WHO-Like Compliance Tool for the Accurate Assessment of HH Compliance. (K-4094) 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Infectious Diseases Society of America Annual Meeting, Washington. October 2008.
118. Johnson DF, Druce J, Birch C, Grayson ML. Assessing the Quantitative Efficiency of Surgical Masks (SM) vs N95 Masks (N95-M) in filtering Respiratory Secretions Among Patients with Acute *Influenza A and B*. (K-4206) 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Infectious Diseases Society of America Annual Meeting, Washington. October 2008.
119. Holmes NE, Howden BP, Grayson ML, Johnson PDR. Do Not Resuscitate (DNR) Orders and 30-Day Mortality in Patients with *Staphylococcus aureus* Bacteraemia (SAB). (K-262) 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 2009.

120. Gordon CL, Johnson PDR, Permezel M, Holmes N, Gutteridge G, McDonald C, Eisen D, Stewardson AJ, Edington J, Charpes PGP, Crinis N, Black MJ, Grayson ML. Association between Severe Swine-origin Influenza A Virus (S-OIV) Infection and Immunoglobulin G₂ Subclass Deficiency. (LB V-1269b) 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 2009.
121. Grayson ML. 24 month outcomes from the Australian national hand hygiene initiative (NHHI). Australian Society for Infectious Diseases Annual Scientific Meeting, Lorne Victoria. March 2011.
122. Stewardson A, Allegranzi B, Grayson ML, Larson E, Voss A, Pittet D. Capturing the ability of a healthcare facility to successfully promote hand hygiene: a new self-assessment instrument. (K-507). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston. September 2010.
123. Grabsch EA, Mahony AA, Cameron DRM, Kennon J, Martin RD, Heland M, Petty MT, Xie S, Grayson ML. Reduction in rates of vancomycin-resistant enterococci (VRE) after introduction of a program of hospital-wide routine bleach cleaning and modified gown/glove protocols. (K-508). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston. September 2010.
124. Grabsch EA, Mahony AA, Cameron DRM, Kennon J, Martin RD, Heland M, Petty MT, Xie S, Grayson ML. Reduction in rates of vancomycin-resistant enterococci (VRE) after introduction of a program of hospital-wide routine bleach cleaning and modified gown/glove protocols. (K-508). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston. September 2010.
125. Gordon CL, Torresi J, Barr I, Charles PG, Edington J, Johnson PDR, Grayson ML. Influenza-Specific Antibody (I-S Ab) Responses in Patients with Immunoglobulin G₂ (IgG₂) Subclass Deficiency and Pandemic 2009 Influenza A (H1N1) Infection. . (V-424). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston. September 2010.
126. Grayson ML, Ballard SA, Gao W, Khumra S, Ward P, Johnson PDR, Grabsch EA. Quantitative efficacy of alcohol-based handrub against vancomycin-resistant enterococci (VRE) on the hands of human volunteers. (K-1131). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September 2011.
127. Cheah AL, Peel T, Howden B, Spelman D, Grayson ML, Spelman T, Liew D, Nation RL, Kong D. Treatment of vanB vancomycin-resistant enterococcal bacteraemia (VREB): factors influencing clinical and economic outcomes. (K-1480). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. September 2011.
128. Grayson ML. Keynote lecture: *Back to the Future: Antibiotics are dead – so how will we manage?* Australian Society for Antimicrobials. Brisbane, Australia, February 2012.
129. Grayson ML. Keynote lecture. 21st National Conference on Nosocomial Infection of Chinese Preventive Medicine Association (CPMA) and the 8th Shanghai International Forum of Infection Control (SIFIC). 23-26th May 2012. Jinan, China.
130. Ryan K, Russo PL, Williams D, Heard K, Bellis K, Havers S, Grayson ML. Hand hygiene compliance (HHC) Results Using Before-After (B-A) Auditing Appear Inaccurate Compared to the WHO 5 Moments Auditing Tool (5M) in Intense Care Settings. (K-2084a). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 2012.
131. Trevillyan J, Angus P, Shelton E, Whitlam J, Ierino F, Pavlovic J, Gregory D, Urbancic K, Torresi J, Testro A, Grayson ML. Use of Electronic Estimation of Renal Function (eGFR) to Guide Valganciclovir (VGCV) dosing in Solid-Organ Transplant Recipients (SOT-R) commonly results in Sub-Therapeutic Ganciclovir (GCV) levels. (T-369). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. September 2012.
132. Grayson ML. Keynote lecture. 6th International Congress of the Asia Pacific Society of Infection Control. 10-13th April 2013. Shanghai, China.
133. Gallagher DP, Davey P, Bergin C, Grayson ML. Bed-day and cost savings for the Irish healthcare system from outpatient parenteral antimicrobial therapy. (P 893). 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany. 27-30th April 2013.
134. Holmes N, Ballard S, Lam M, Johnson PDR, Grayson ML, Stinear T, Howden B. Emergence of teicoplanin resistance among vanB vancomycin-resistant *Enterococcus faecium* isolates in a cluster of solid organ transplant

recipients: risk factors and molecular characterisation. (P 2154). 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany. 27-30th April 2013.

135. Grayson ML. Keynote lecture: *Antibiotics are dead: how will we manage?* (K454). 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany. 27-30th April 2013.
136. Grayson ML. Keynote lecture: *The Australian Hand Hygiene Initiative*. International Consortium for Prevention and Infection Control (ICPIC), Geneva, CH. July 2013
137. Kwong J, Grabsch E, Holmes, N, Ward, P, Xie S, Cameron D, Johnson P, Grayson ML, Howden B. Clinical and Microbiological Predictors of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) in *Staphylococcus aureus* Bacteremia (SAB). (D-119). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver. September 2013.
138. Hewitt NH, Urbancic KF, Grigg AP, Grayson ML. Detailed Antifungal Stewardship (AFS) Is Key to Achieving Excellent Plasma Levels During Oral Posaconazole (PCZ) Prophylaxis in High Risk Hematology Patients. (M-239). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver. September 2013.
139. Grayson ML, Russo P, Heard K, Ryan K, Havers S, Cruickshank M. Comparison of the WHO 5 Moments (5M) Versus Entry-Exit (E-E) Auditing Tools Using the Hand Hygiene Australia (HHA) National Compliance Database (2009-2012). (K-440). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver. September 2013.
140. Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton D, Zeglinski PT, Frauman AG, Grayson ML. Oral Fosfomycin Tromethamine (FOS) Achieves Good Intra-Prostate Levels Suggesting it May Be a Prophylaxis & Treatment Option for Multidrug-Resistant (MDR) Prostatitis. (A-1045). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver. September 2013.
141. Grayson ML. Infection control and it's impact on AMR (invited keynote). Australian Society for Microbiology Annual Scientific Meeting. Melbourne, July 2014
142. Macesic N, Urbancic K, Ierino F, Grayson ML. High rates of adverse reactions with aerosolized pentamidine use for pneumocystis pneumonia prophylaxis in renal transplant recipients. (T-471). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. September 2014.
143. Macesic N, Ameratunga M, Johnson D, Grayson ML. Braf and Mek inhibitors used in metastatic melanoma frequently cause a syndrome mimicking sepsis. (T-1801). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. September 2014.
144. Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. (A-004). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. September 2014.
145. Pitcher JI, McLellan JE, Ballard SA, Grabsch EA, Grayson ML. Superbugs in the supermarket? Assessing the rate of contamination with multidrug-resistant (MDR) Gram-negative bacteria (GNB) in fresh Australian chicken and pork. (C-746). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington. September 2014.
146. Grayson ML. Use of an innovative personality-profiling tool to guide implementation of infection control strategies among different healthcare worker groups – Why colours matter. (S-409). 55th Interscience Conference on Antimicrobial Agents and Chemotherapy & ICC, San Diego. September 2015.
147. Trubiano JA, Chen C, Grayson ML, Cheng AC, Thursky KA. Assessing the Impact of Antimicrobial Allergy on Antimicrobial Stewardship- A National Antimicrobial Prescribing Survey. (S-048). 55th Interscience Conference on Antimicrobial Agents and Chemotherapy & ICC, San Diego. September 2015.
148. Tedjaseputra A, Murphy MA, Grabsch EA, Leroi MJ, Ballard SA, Grayson ML. Assessing the Rate of Faecal Carriage of ESBL-positive Gram-Negative Bacteria (ESBL-GNB) in High Risk Australian Haematology and Liver Transplant Patients to Assist with Antimicrobial Stewardship. (S-413) 55th Interscience Conference on Antimicrobial Agents and Chemotherapy & ICC, San Diego. September 2015.

149. Grayson ML. Public Lecture: “Superbugs”. Australasian Society for Infectious Diseases Annual Scientific Conference. Launceston, TAS. April 2016.
150. Grayson ML. How should we treat ESBL pathogens in prostatitis? Session: New insights into urinary tract infections. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy & Microbe. Boston, 19th June 2016. Symposium Session 351.
151. Grayson ML. Implementation of the Best Infection Control Practices: Worldwide Progress Reports - The Australian Perspective. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy & Microbe. Boston, 20th June 2016. Symposium Session 441.

Non-Professional Interests

Woodworking - furniture making from recycled timber
Farming – hardwood plantations and forest restoration; sheep
Bushwalking and snow skiing;
Squash